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A B S T R A C T
Background
Pre-cancerous lesions of cervix (cervical intraepithelial neoplasia (CIN)) are usually treated with excisional or ablative procedures. In
the UK, the NHS cervical screening guidelines suggest that over 80% of treatments should be performed in an outpatient setting
(colposcopy clinics). Furthermore, these guidelines suggest that analgesia should always be given prior to laser or excisional treatments.
Currently various pain relief strategies are employed that may reduce pain during these procedures.
Objectives
The aim of this review was to assess whether the administration of pain relief reduced pain during colposcopy treatment and in the
postoperative period.
Search methods
We searched the Cochrane Gynaecological Cancer Review Group Specialised Register, Cochrane Central Register of Controlled Trials
(CENTRAL - May 2011) (2011, Issue 2), MEDLINE (1950 to May week 2, 2011), EMBASE (1980 to week 20, 2011) for studies of
any design relating to analgesia for colposcopic management. We also searched registers of clinical trials, abstracts of scientific meetings,
reference lists of included studies and contacted experts in the field.
Selection criteria
Randomised controlled trials (RCTs) that compared all types of pain relief before, during or after outpatient treatment to the cervix,
in adult women with CIN undergoing loop excision, laser ablation, laser excision or cryosurgery in an outpatient colposcopy clinic
setting.
Data collection and analysis
We independently assessed study eligibility, extracted data and assessed risk of bias. We entered data into RevMan and double checked
it for accuracy. Where possible, the results were expressed as mean pain score and standard error of the mean with 95% confidence
intervals (CI) and the data were synthesised in a meta-analysis.
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Main results
We included 17 RCTs (1567 women) of varying methodological quality in the review. These trials compared a variety of interventions
aimed at reducing pain in women who underwent treatment for CIN, including cervical injection with lignocaine alone, lignocaine
with adrenaline, prilocaine with felypressin, oral analgesics (non-steroidal anti-inflammatory drugs (NSAIDs)), inhalation analgesia
(gas mixture of isoflurane and desflurane), lignocaine spray, cocaine spray, local application of benzocaine gel, lignocaine-prilocaine
cream (EMLA cream) and transcutaneous electrical nerve stimulation (TENS).
Most comparisons were restricted to single trial analyses and were under-powered to detect differences in pain scores between treatments
that may or may not have been present. There was no significant difference in pain relief between women who received local anaesthetic
infiltration (lignocaine 2%; administered as a paracervical or direct cervical injection) and a saline placebo (2 trials; 130 women; MD -
13.74; 95% CI -34.32 to 6.83). However, when local anaesthetic was combined with a vasoconstrictor agent (one trial used lignocaine
combined with adrenaline while the second trial used prilocaine combined with felypressin), significantly less pain (on visual analogue
scores) occurred compared with no treatment (2 trials; 95 women; MD -23.73; 95% CI -37.53 to -9.93). Comparing two preparations
of local anaesthetic plus vasoconstrictor, prilocaine combined with felypressin did not differ from lignocaine combined with adrenaline
for its effect on pain control (1 trial; 200 women; MD -0.05; 95% CI -0.26 to 0.16). Although the mean observed blood loss score was
less with lignocaine plus adrenaline (1.33 ± 1.05) as compared with prilocaine plus felypressin (1.74 ± 0.98), the difference was not
clinically significant as the overall scores in both groups were low (1 trial; 200 women; MD 0.41; 95% CI 0.13 to 0.69). Inhalation of
gas mixture (isoflurane and desflurane) in addition to standard cervical injection with prilocaine plus felypressin resulted in significantly
less pain during the LLETZ (loop excision of the transformation zone) procedure (1 trial; 389 women; MD -7.20; 95% CI -12.45 to
-1.95). Lignocaine plus ornipressin resulted in significantly less measured blood loss (1 trial; 100 women; MD -8.75; 95% CI -10.43
to -7.07) and a shorter duration of treatment (1 trial; 100 women; MD -7.72; 95% CI -8.49 to -6.95) than cervical infiltration with
lignocaine alone.
One meta-analysis found no statistically significant difference in pain using visual analogue scores between women who received oral
analgesic and those who received placebo (2 trials; 129 women; MD -3.51; 95% CI -10.03 to 3.01; Analysis 6.1).
Cocaine spray was associated with significantly less pain (1 trial; 50 women; MD -28; 95% CI -37.86 to -18.14) and blood loss (1
trial; 50 women; MD 0.04; 95% CI 0 to 0.70) than placebo.
No serious adverse events were reported in any of the trials and majority of trials were at moderate or high risk of bias (n = 12).
Authors’ conclusions
Based on two small trials, there was no significant difference in pain relief in women receiving oral analgesics compared with placebo
or no treatment (129 women; MD -3.51; 95% CI -10.03 to 3.01). We consider this evidence to be of a low to moderate quality. In
routine clinical practice, intracervical injection of local anaesthetic with a vasoconstrictor (lignocaine plus adrenaline or prilocaine plus
felypressin) appears to be the optimum analgesia for treatment. However, further high-quality, adequately powered trials should be
undertaken in order to provide the data necessary to estimate the efficacy of oral analgesics, the optimal route of administration and
dose of local anaesthetics.
P L A I N L A N G U A G E S U M M A R Y
Pain relief for women with pre-cancerous changes of the cervix (cervical intraepithelial neoplasia (CIN)) undergoing outpatient
treatment
Treatment for CIN is usually undertaken in an outpatient colposcopy clinic to remove the pre-cancerous cells from the cervix. It
commonly involves lifting the cells off the cervix with electrically heated wire (diathermy) or laser, or destroying the abnormal cells
with freezing methods (cryotherapy). This is potentially a painful procedure. The purpose of this review is to determine which, if any,
pain relief should be used during cervical colposcopy treatment. We identified 17 trials and these reported different forms of pain
relief before, during and after colposcopy. Evidence from two small trials showed that women having a colposcopy treatment had less
pain and blood loss if the cervix was injected with a combination of a local anaesthetic drug and a drug that causes blood vessels to
constrict (narrow), compared with placebo. Although taking oral pain-relieving drugs (e.g. ibuprofen) before treatment on the cervix in
the colposcopy clinic is recommended by most guidelines, evidence from two small trials did not show that this practice reduced pain
during the procedure. Most of the evidence in this field is of a low to moderate quality and further research may change these findings.
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Additionally, we were unable to obtain evidence with regards to dosage of the local anaesthetic drug or method of administering local
anaesthetic into the cervix. There is need for high-quality trials with sufficient numbers of participants in order to provide the data
necessary to estimate these effects.
B A C K G R O U N D
Description of the condition
Cervical cancer is the secondmost common cancer among women
up to 65 years of age and is the most frequent cause of death from
gynaecological cancers worldwide. A woman’s risk of developing
cervical cancer by the age of 65 years ranges from 0.69% in devel-
oped countries to 1.38% in developing countries (GLOBOCAN
2008). In Europe, about 60% of women with cervical cancer
are alive five years after diagnosis (EUROCARE 2003). Cervi-
cal screening has all the characteristics of a good screening pro-
gramme. There are effective screening tests, such as the traditional
cytological approach (Pap smear) for diagnosing pre-invasive and
early invasive disease, or new methodologies, such as human pa-
pillomavirus (HPV) testing, which try to improve sensitivity and
specificity. Also there are effective surgical treatments for pre-inva-
sive and early invasive disease, which dramatically alter the prog-
nosis. As cervical screening is relatively inexpensive, non-invasive
and treatment of pre-invasive disease requires only simple sur-
gical techniques, screening is cost-effective and has been clearly
demonstrated to reducemortality in countries with well-organised
screening programmes (Peto 2004).
The effectiveness of different modalities of treatment for pre-in-
vasive disease has been the subject of a previous Cochrane re-
view (Martin-Hirsch 2010). In this review, each modality of treat-
ment was assessed for its ability to eradicate disease and associ-
ated morbidity. Current treatment for cervical intraepithelial neo-
plasia (CIN) is by local ablative therapy or by excisional meth-
ods, depending on the nature and extent of the disease. There is
an international consensus that the majority of these procedures
can be performed within the colposcopy clinic in an outpatient
setting. In the UK, the National Health Service (NHS) cervical
screening guidelines suggest that over 80% of treatments should
be performed in a clinic setting (NHSCSP 2004;NHSCSP2010).
Furthermore, these guidelines also suggest that analgesia should
always be given prior to laser or excisional treatments.
Description of the intervention
Therapies that are available to treat pre-malignant lesions of the
cervix in outpatient settings include loop diathermy excision, laser
ablation or excision and cryotherapy (Martin-Hirsch 2010). Stud-
ies have reported variable outcomes with different types of pain
relief for these procedures. The choice of pain relief in these
studies varies from no analgesia to intracervical infiltration with
anaesthetic agent (e.g. lignocaine or prilocaine) with or with-
out vasopressor agents (e.g. adrenaline or felypressin) (Lee 1986;
Johnson 1989). Other methods studied are oral therapy with
non-steroidal anti-inflammatory drugs (NSAIDs) (Frega 1994),
local spray with cocaine (Mikhail 1988), topical benzocaine gel
(Lipscomb 1995), inhalation of gas mixture of isoflurane and
desflurane (Cruickshank 2005), local anaesthetic cream (EMLA
cream) (Sarkar 1993) and transcutaneous electrical nerve stimula-
tion (TENS) (Crompton 1992).
How the intervention might work
The possiblemechanisms proposed in the literature to explain pain
during cervical laser vaporisation includes pain mediated through
peripheral pain fibres in the cervix, stimulated by heat energy, with
or without pain caused by increased uterine contractions, probably
because of the release of prostaglandins. The interventions may
work by blocking the pain pathways. The nerve supply to the cervix
is unclear, but the richest supply appears to be at the level of internal
os. The ectocervix appears to be relatively insensitive to extremes
of temperature with few specialised nerve fibres (Jordan 1976).
Pain stimuli from the cervix and vagina are conducted by visceral
afferent fibres to the S2 to S4 spinal ganglia via the pudendal
and pelvic splanchnic nerves, along with parasympathetic fibres
(Moore 2006).
Why it is important to do this review
There now appears to be a consensus that analgesia should be ad-
ministered before treatment to the cervix. Currently, there is no
systematic review or meta-analysis evaluating whether administer-
ing analgesia reduces the pain experienced by patients undergoing
outpatient treatment. Most guidelines are also not explicit on the
nature of optimum analgesia for intra- and postoperative pain re-
lief. Analgesia is commonly administered intra- or para-cervically
using fine dental needles. Other routes of administering analgesics
evaluated are TENS, peri-operative NSAIDs and inhalation anal-
gesia.
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O B J E C T I V E S
To assess whether the administration of anaesthesia reduces pain
during colposcopy treatment and in the postoperative period.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs)
Types of participants
Women with CIN undergoing loop excision, laser ablation, laser
excision or cryosurgery treatment of the cervix in an outpatient
colposcopy clinic setting.
Types of interventions
All types of pain relief before, during or after outpatient treatment
to the cervix, compared with no pain relief or another type of
pain relief. Any studies that included treatment performed under
general anaesthetic were excluded.
Types of outcome measures
Primary outcomes
Presence or absence of pain, as a dichotomous outcome, or the
degree of pain, measured by visual analogue scores or categorical
scales.
Secondary outcomes
1. Speed of procedure (in minutes).
2. Blood loss (either in mL or categorical scale as none, mild
or minimal, heavy, troublesome or as dichotomous data).
3. Any moderate or severe adverse effects (dizziness, fainting,
shaking, delayed discharge, etc.).
Search methods for identification of studies
We searched for papers in all languages and translations were un-
dertaken, if necessary.
Electronic searches
A search strategy was used to identify relevant RCTs.
We searched the Cochrane Gynaecological Cancer Review Group
Specialised Register, Cochrane Central Register of Controlled Tri-
als (CENTRAL) (2011, Issue 2), MEDLINE (1950 to May week
2, 2011), EMBASE (1980 to week 20, 2011) for studies of any
design relating to analgesia for colposcopic management. The
electronic literature search strategies for CENTRAL, MEDLINE
and EMBASE are summarised in Appendix 1, Appendix 2 and
Appendix 3, respectively.
All relevant articles found were identified on PubMed and using
the ’related articles’ feature, further searches were carried out for
newly published articles.
Searching other resources
Registries of randomised trials
We searched the following registries for ongoing trials:
Metaregister (www.controlled-trials.com/mrct/), Physicians Data
Query (www.ncbi.nlm.nih.gov/), www.clinicaltrials.gov and
www.cancer.gov/clinicaltrials.
Conference proceedings and abstracts were searched through ZE-
TOC (http://zetoc.mimas.ac.uk).
Handsearching
The citation lists of included studies, key textbooks and previous
systematic reviews were handsearched.
Reports of conferenceswere handsearched in the following sources:
• Gynecologic Oncology (Annual Meeting of the American
Society of Gynecologic Oncologist);
• International Journal of Gynecological Cancer (Annual
Meeting of the International Gynecologic Cancer Society);
• British Society for Colposcopy and Cervical Cytology
(BSCCP) Annual Meeting.
Data collection and analysis
Selection of studies
Two review authors (KG, AB) scanned the titles and abstracts
(when available) of all reports identified through the electronic
searches. For studies appearing to meet the inclusion criteria, or
for which there were insufficient data in the title and abstract to
make a clear decision, the full report was obtained. Two review
authors (KG, AB) assessed the full reports obtained from all the
electronic and other methods of searching were assessed indepen-
dently to establish whether the studies met the inclusion criteria or
not. Disagreements were resolved by discussion. Where resolution
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was not possible, a third review author (PM-H) was consulted. All
studies meeting the inclusion criteria underwent validity assess-
ment and data extraction using a standardised proforma. Studies
rejected at this or subsequent stages were recorded in the table of
excluded studies, and reasons for exclusion recorded.
Data extraction and management
Two review authors (KG, AB) extracted the data independently
using specially designed data extraction forms. The data extraction
forms were piloted on several papers and modified as required be-
fore use. Any disagreements were discussed and a third review au-
thor (PM-H) consulted when necessary. Study authors were con-
tacted for clarification or missing information if necessary. Data
were excluded until further clarification was available or if agree-
ment could not be reached.
For included studies, data were abstracted as recommended in
Chapter 7 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). This included data on the following:
• author, year of publication, country of origin, source of
study funding and journal citation (including language);
• setting;
• details of the participants including demographic
characteristics (e.g. age, co-morbidities, etc.), total number
enrolled and criteria for inclusion and exclusion;
• CIN details at diagnosis;
• details of the type of intervention;
• risk of bias in study (see below);
• duration of follow-up;
• details of the outcomes reported (pain, blood loss, adverse
events), including method of assessment, and time intervals (see
below):
◦ for each outcome: outcome definition (with diagnostic
criteria if relevant);
◦ unit of measurement (if relevant);
◦ for scales: upper and lower limits, and whether high or
low score is good;
◦ results: number of participants allocated to each
intervention group;
◦ for each outcome of interest: sample size; missing
participants;
◦ the time points at which outcomes were collected and
reported were noted.
Data on outcomes were extracted as below:
• for dichotomous outcomes (e.g. pain, adverse events), we
extracted the number of women in each treatment arm who
experienced the outcome of interest and the number of women
assessed at endpoint, in order to estimate a risk ratio (RR);
• for continuous outcomes (e.g. blood loss), we extracted the
final value and standard deviation (SD) of the outcome of
interest and the number of women assessed at endpoint in each
treatment arm at the end of follow-up, in order to estimate the
mean difference (MD) (if trials measured outcomes on the same
scale) or standardised mean differences (if trials measured
outcomes on different scales) between treatment arms and its
standard error.
Where possible, all data extracted were those relevant to an inten-
tion-to-treat (ITT) analysis, in which participants are analysed in
groups to which they were assigned.
Assessment of risk of bias in included studies
The risk of bias in included RCTs was assessed in accordance with
guidelines in the Cochrane Handbook for Systematic Reviews of In-
terventions using theCochraneCollaboration’s tool and the criteria




• blinding (of participants, healthcare providers and outcome
assessors);
• incomplete outcome data:
◦ we recorded the proportion of women whose
outcomes were not reported at the end of the study. We coded
the satisfactory level of loss to follow-up for each outcome as:
⋄ low risk of bias, if fewer than 20% of women
were lost to follow-up and reasons for loss to follow-up were
similar in both treatment arms;
⋄ high risk of bias, if more than 20% of women
were lost to follow-up or reasons for loss to follow-up were
different between treatment arms;
⋄ unclear risk of bias, if loss to follow-up was not
reported;
• selective reporting of outcomes;
• other possible sources of bias.
Two review authors (KG, AB) applied the ’Risk of bias’ tool in-
dependently and differences were resolved by discussion or by ap-
peal to a third review author (PM-H). Results were summarised in
both a ’Risk of bias’ graph and a ’Risk of bias’ summary. Results of
meta-analyses were interpreted with consideration of the findings
with respect to risk of bias.
Measures of treatment effect
We used the following measures of the effect of treatment:
• for dichotomous outcomes, we used the RR;
• for continuous outcomes, we used the MD between
treatment arms.
Unit of analysis issues
Two review authors (KG, AB) reviewed any unit of analysis issues
according to Higgins 2011 and differences were resolved by dis-
cussion.
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Dealing with missing data
We did not impute missing outcome data for the primary out-
come. If data were missing or only imputed data were reported
we contacted trial authors to request data on the outcomes only
among women who were assessed.
Assessment of heterogeneity
We assessed heterogeneity between studies by visual inspection of
forest plots, by estimation of the percentage heterogeneity between
trials that could not be ascribed to sampling variation (Higgins
2003), by a formal statistical test of the significance of the hetero-
geneity (Deeks 2001) and, when possible, by subgroup analyses.
If there was evidence of substantial heterogeneity, we investigated
and reported the possible reasons.
Data synthesis
Each trial was characterised by its type of analgesia and route of
administration. Furthermore, the assessment of pain or any other
outcomes were classified on whether dichotomous or continuous
outcomes were used. Meta-analysis was only performed, when the
interventions, route of administration and outcomemeasures were
clinically similar.
• For any dichotomous outcomes, the RR was calculated for
each trial and these were then pooled.
• For continuous outcomes, the MDs between the treatment
arms at the end of follow-up were pooled if all trials measured
the outcome on the same scale, otherwise standardised mean
differences were pooled.
If any trials had multiple treatment groups, the ’shared’ compari-
son group was divided into the number of treatment groups and
comparisons between each treatment group and the split compar-
ison group was treated as independent comparisons.
Random-effects models with inverse variance weighting were used
for all meta-analyses (DerSimonian 1986).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The search strategy identified 232 unique references. Two review
authors (KG, AB) read the abstracts of these and articles that ob-
viously did not meet the inclusion criteria were excluded at this
stage. Twenty articles were retrieved in full and translated into En-
glish where appropriate and updated versions of relevant studies
were identified. The full-text screening of these 20 references ex-
cluded a further two references for the reasons described in the
table Characteristics of excluded studies. However, 18 references
reporting on 17 completed RCTs were identified that met our
inclusion criteria and are described in the table Characteristics of
included studies.
Searches of the grey literature did not identify any additional trials.
Included studies
The 17 included trials (Al Kurdi 1985; Connell 2000; Crompton
1992; Cruickshank 2005; Diakomanolis 1997; Duncan 2005;
Frega 1994; Howells 2000; Johnson 1989; Johnson 1996; Lee
1986; Lipscomb 1995; Mikhail 1988; Rogstad 1992; Sammarco
1993; Sarkar 1993; Winters 2009) randomised 1600 eligible
women, of whom 1567 were assessed at the end of the trials
(Characteristics of included studies; Table 1)
Design
All trials were conducted as single centre trials in a colposcopy
clinic setting. Various pain relief interventionswere reported in the
17 included trials. Two trials (Johnson 1989; Rogstad 1992) inves-
tigated cervical injection (intracervical and paracervical block, re-
spectively) with anaesthetic agent (lignocaine 2%) compared with
saline. Three trials (Duncan 2005; Lee 1986; Sammarco 1993)
used preparations made up of local anaesthetic plus vasoconstric-
tor. One of these three trials used cervical injection with ligno-
caine 1% mixed with 1:100,000 dilution of adrenaline given sub-
mucosally and compared it with no treatment (Sammarco 1993),
while two other trials (Duncan 2005; Lee 1986) reported cervical
injection with a different anaesthetic agent (prilocaine 30 mg/mL)
mixed with vasoconstrictor (felypressin 0.03 IU/mL) compared
with no treatment or placebo. Lignocaine 1% with vasoconstric-
tor (1:30 of ornipressin in lignocaine 1% solution) compared to
lignocaine 1% alone was investigated in one trial (Diakomanolis
1997) to evaluate the effects on the blood loss during the proce-
dure.
Three trials investigated the method of cervical injection. In one
trial local anaesthetic combined with vasoconstrictor (prilocaine
3%plus felypressin) administered by deep and superficial injection
was compared with deep injection alone (Winters 2009), while in
another trial paracervical injection of lignocaine 2%was compared
with direct injection (Johnson 1996). Two different preparations
of anaesthetic agent with vasoconstrictor (prilocaine 30 mg/mL
plus felypressin 0.03 IU/mL compared with lignocaine 2% plus
adrenaline 1:80,000) was investigated in a third trial (Howells
2000).
The use of oral analgesia withNSAID (naproxen sodium, dose 550
mg), given half an hour to one hour before treatment, compared
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to placebo or no treatment was reported in two trials (Al Kurdi
1985; Frega 1994) with one trial (Frega 1994) using a single dose
of naproxen sodium 550 mg while the other trial (Al Kurdi 1985)
used double the dose (1100 mg).
One trial (Cruickshank 2005) used a gas mixture (isoflurane 0.3%
and desflurane 1%) as inhalation agent, in addition to standard
cervical injection of local anaesthetic plus vasoconstrictor (prilo-
caine 30 mg/mL plus felypressin 0.03 IU/mL, also known as oc-
tapressin).
A further four trials (Connell 2000; Lipscomb 1995; Mikhail
1988; Sarkar 1993) used topical application of gel, cream and
sprays for their anaesthetic effects during the treatment on cervix.
One trial looked at the effects of benzocaine 20% gel (Lipscomb
1995) compared to placebo gel and the other trial compared
EMLA cream, which is a local anaesthetic cream consisting of a
mixture of lignocaine 2.5% and prilocaine 2.5% (Sarkar 1993) to
a placebo cream. Mikhail 1988 compared 3 to 4 mL of a cocaine
10% spray as a surface anaesthesia to a placebo solution (preser-
vative) for its effects on pain relief. In the trial of Connell 2000,
women were randomised to receive either lignocaine hydrochlo-
ride 10% spray or saline in addition to standard cervical infil-
tration using prilocaine 30 mg/mL plus felypressin 0.03 IU/mL.
TENS, a non-invasive method, was also investigated (Crompton
1992).
Participant characteristics
The age of the women in the included trials ranged from 17
to 60 years; the mean age across the trials ranged from 27 to
35 years. Both pre- and postmenopausal women were included
in the majority of the studies, although two trials (Crompton
1992; Johnson 1989) excluded perimenopausal, postmenopausal
women, or both. Other common exclusion criteria were: various
allergies, pregnancy and previous treatment to the cervix. Con-
comitant use of highly protein-bound drug was an exclusion crite-
ria in one trial (Al Kurdi 1985) with oral analgesia using NSAID,
while another trial using a gas mixture of isoflurane and desflu-
rane (Cruickshank 2005) excluded women on monoamine-oxi-
dase inhibitors or women driving themselves home from the clinic.
Pelvic inflammatory disease, cardiac pacemaker (Crompton 1992),
bronchial asthma (Al Kurdi 1985), cardiac conditions, hyperten-
sion and epilepsy (Diakomanolis 1997) were other reasons for ex-
cluding patients from trials.
Parity was described in patient characteristics for intervention and
control group in theCrompton 1992; Cruickshank 2005;Duncan
2005: Howells 2000; Lipscomb 1995 and Johnson 1989 trials.
Number of nulliparous women recruited in these trials ranged
from 18% to 48%. Two trials (Lipscomb 1995; Mikhail 1988)
reported the number of children, which ranged from no children
up to five. Marital status was provided in Duncan 2005, Mikhail
1988 and Sarkar 1993 trials; whereas the usage of contraception
was provided in Howells 2000 and Johnson 1989. Sixty-five per
cent of women in the intervention group and 72% in the control
group used contraception in the trial of Howells 2000. The use of
oral contraceptive pills in Johnson 1989 was 47% in the interven-
tion group compared to 53% in the control group.
Cruickshank 2005 used depravation scores, while median anxiety
Hospital Anxiety and Depression (HAD) score (Zigmond 1983)
and median depression HAD score (Zigmond 1983) was used to
compare the characteristics of intervention and control groups in
the Crompton 1992 and Johnson 1989 trials. The Johnson 1989
trial also used anxiety visual analogue score (Zigmond 1983) and
premenstrual syndrome scores (no reference provided). Anxiety
score (Spielberger 1970) was also used in the trial of Lee 1986.
Only one trial (Howells 2000) compared the groups for smoking
status.
Two trials (Howells 2000; Winters 2009) reported smear grades
as well as final histology with CIN grades. Lipscomb 1995 and
Winters 2009 reported positive margins of excised cervical spec-
imen after treatment. The size of the cervical pre-invasive lesion
was reported in patients’ characteristics by Crompton 1992, while
Howells 2000 reported the size of the loop excised. Passes of loop
diathermy were provided by Howells 2000 with 76% in the inter-
vention group and 75% in the control group having one pass of
the loop. Lipscomb 1995 reported average number of loop passes
per person in trial and control group.
In nine of the 17 trials, women underwent laser ablation of cervix
(Al Kurdi 1985; Crompton 1992; Diakomanolis 1997; Frega
1994; Johnson 1989; Johnson 1996; Lee 1986; Mikhail 1988;
Sarkar 1993), in five trials LLETZ was used (Cruickshank 2005;
Howells 2000; Lipscomb 1995; Winters 2009; Connell 2000),
cryotherapy in one trial (Sammarco 1993) and in two trials cold
coagulation with Semm Coagulator was used to treat the cervix
(Duncan 2005; Rogstad 1992).
Outcomes
The diverse nature of the interventions in the trials precluded
direct comparison apart from two trials (Al Kurdi 1985; Frega
1994) comparing oral analgesia versus control, it was possible to
combine the pain relief outcome reported on visual analogue scale
(VAS).
Pain relief reported on visual analogue scale (VAS)
For the included studies, the degree of pain relief during the pro-
cedure was reported as VAS in 13 trials (Al Kurdi 1985; Connell
2000; Cruickshank 2005; Frega 1994; Johnson 1989; Johnson
1996; Lee 1986; Lipscomb 1995; Mikhail 1988; Rogstad 1992;
Sammarco 1993; Sarkar 1993; Winters 2009). In all trials VAS
scores were assessed immediately after the procedure. Five trials
(Al Kurdi 1985; Cruickshank 2005; Lipscomb 1995; Sarkar 1993;
Winters 2009) used a 100-mm or 10-cm linear analogue scale,
where 0 was no pain at all and 100 (or 10 in the 10-cm scale) was
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worst pain imaginable. One trial (Johnson 1989) reported pain re-
lief on 120-mm visual linear analogue scale, which was converted
to percentages. Johnson 1996 and Connell 2000 reported pain
relief as VAS; however, the values were median and interquartile
range, rather than mean and SD. Sammarco 1993 reported VAS
on an 11-point scale (0 to 10) where 0 was no pain and 10 was
severe pain.
Pain relief reported on verbal rating scores (VRS)
In five trials (Al Kurdi 1985; Diakomanolis 1997; Duncan 2005;
Lee 1986; Mikhail 1988), pain relief was reported on VRS cate-
gorised as none, mild, moderate or severe.
Pain relief reported on other categorical scales
In addition toVAS, Johnson 1989 and Johnson 1996 also reported
pain relief as an objective score, given by the attending nurse and
laser operator on a categorical scale of 0 to 2. In another trial
(Howells 2000), pain was scored by the attending colposcopist on
a categorical scale (0 = none to 4 = severe) as well as by women
undergoing treatment (0 = none to 5 = unbearable). In the Sarkar
1993 trial, pain scores weremeasured for pain relief after treatment
and not just during treatment.However, the time scale for carrying
out the pain score was not specified. In the trial of Al Kurdi 1985,
women were asked whether additional pain killers were required
within the first 24 hours. In Cruickshank 2005 trial, women were
asked whether additional pain relief was required after treatment.
It would appear that this was asked at sixmonths’ follow-up, which
carries a risk of recall bias. Owing to this risk, these data were not
included in the analysis.
Blood loss during treatment
Blood loss was reported as none, mild, moderate and troublesome
in seven trials (Crompton1992;Cruickshank2005;Diakomanolis
1997; Howells 2000; Lee 1986; Mikhail 1988; Sarkar 1993). In
the Diakomanolis 1997 trial, the method of measuring blood
loss was explicitly specified, while other trials (Crompton 1992;
Cruickshank 2005; Howells 2000; Lee 1986; Mikhail 1988;
Sarkar 1993) reported blood loss subjectively as scored by the op-
erator on a categorical scale (0 = none to 5 = heavy/troublesome).
Speed of procedure (or duration of treatment)
Speed of procedure was reported in four trials (Diakomanolis
1997; Howells 2000; Lee 1986; Sarkar 1993).
Anxiety
Preoperative anxiety is one of the most significant risk factors for
experiencing pain during cervical colposcopy treatment (Johnson
1994). In four trials anxiety levels were measured preoperatively
in both arms. Anxiety was measured using HAD scores in three
trials (Crompton 1992; Cruickshank 2005; Johnson 1989), while
a fourth trial (Lee 1986) used a different scale (Spielberger State
Anxiety Inventory) (Spielberger 1970).
Excluded studies
Two references were excluded, after obtaining the full text, for the
following reasons:
• The trial of Sarkar 1990 was excluded as it was not an RCT
and it was not controlled for placebo effects. This trial reported
use of EMLA cream (lignocaine-prilocaine cream) for pain relief
during cervical laser treatment;
• Sharp 2009 was excluded because this study did not
compare pain relief interventions. This was an observational
study nested within an RCT in which women completed
questionnaire about their experiences at colposcopy, colposcopy
and biopsy, and colposcopy and LLETZ treatment.
For further details of all the excluded studies see theCharacteristics
of excluded studies table.
Risk of bias in included studies
Five trials (Connell 2000; Cruickshank 2005; Johnson 1989;
Johnson 1996; Mikhail 1988) were at low risk of bias, as they
satisfied at least five of the criteria that we used to assess risk of bias.
Eight trials (Al Kurdi 1985; Diakomanolis 1997; Duncan 2005;
Howells 2000; Lee 1986; Lipscomb 1995; Sarkar 1993; Winters
2009) were at moderate risk of bias as they satisfied three or four
of the criteria. The trial of Rogstad 1992 was at high risk of bias
as it only satisfied two of the criteria and a further three trials
(Crompton 1992; Frega 1994; Sammarco 1993) were also at high
risk of bias as they only satisfied one criterion (see Figure 1; Figure
2).
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Figure 1. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study.
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Eight trials (Connell 2000; Cruickshank 2005; Johnson 1989;
Johnson 1996; Lipscomb 1995; Mikhail 1988; Rogstad 1992;
Winters 2009) reported the method of generation of the sequence
of random numbers used to allocate women to treatment arms,
but three of these trials (Lipscomb 1995; Mikhail 1988; Rogstad
1992) did not report concealment of this allocation sequence
from patients and healthcare professionals involved in the trial.
Five trials (Al Kurdi 1985; Connell 2000; Frega 1994; Lee 1986;
Sammarco 1993; Sarkar 1993) did not report on either themethod
of sequence generation or concealment of allocation. In the tri-
als of Duncan 2005 and Howells 2000 it was unclear whether
the method of assigning women to treatment groups was car-
ried out using an adequate method of sequence generation, but
the allocation was adequately concealed. The trial of Crompton
1992 did not report sequence generation details but did state
that the allocation was not concealed. Three trials (Cruickshank
2005; Johnson 1989; Johnson 1996) reported blinding of patients,
healthcare professionals and outcome assessors, whereas this in-
formation was not reported in five trials (Al Kurdi 1985; Duncan
2005; Frega 1994; Lee 1986; Rogstad 1992). Five trials (Connell
2000; Diakomanolis 1997; Lipscomb 1995;Mikhail 1988; Sarkar
1993) confirmed blinding of patients and healthcare professionals,
but it was unclear whether the outcome assessor was blinded and
a further four trials (Crompton 1992; Howells 2000; Sammarco
1993; Winters 2009) confirmed that at least one of patients and
health care professionals were not blinded but did not report
whether the outcome assessor was blinded or not. It was not certain
whether three trials (Crompton 1992; Lipscomb 1995; Sammarco
1993) reported all the outcomes that they assessed, but in 10 trials
(Connell 2000; Cruickshank 2005; Diakomanolis 1997; Duncan
2005; Frega 1994; Howells 2000; Johnson 1989; Johnson 1996;
Rogstad 1992; Winters 2009) it appeared that additional perti-
nent outcomes should have been reported and their omission left
a gap in the evidence. The remaining four trials seemed to report
all relevant outcomes related to the subject matter. No other form
of bias appeared likely in 10 trials (Al Kurdi 1985; Connell 2000;
Cruickshank 2005; Duncan 2005; Howells 2000; Johnson 1989;
Lee 1986; Lipscomb 1995; Mikhail 1988; Winters 2009). Addi-
tional forms of bias seemed a possibility in the trials of Sammarco
1993 and Sarkar 1993 in the way some analyses were undertaken,
but it was unclear whether this was the case in the remaining five
trials. At least 80% of women who were enrolled were assessed at
endpoint in all 17 trials.
Effects of interventions
Local anaesthetic (lignocaine 2%) versus placebo
(saline injection)
Pain scores during procedure (VAS)
Two trials (Johnson 1989; Rogstad 1992) compared the effects
of local anaesthetic lignocaine 2% without a vasoconstrictor to
placebo (saline injection). The trial of Johnson 1989 used ligno-
caine 2% injection for paracervical block while the trial of Rogstad
1992 used lignocaine 2% for direct injection in the cervix. The
trial of Rogstad 1992 found that women who received local anaes-
thetic had significantly less pain during treatment than women
who received saline injection (60 women; MD -24.00; 95% CI -
35.44 to -12.56), whereas the Johnson 1989 trial found no statis-
tically significant difference between the same groups (70 women;
MD -3.00; 95% CI -16.03 to 10.03) (Analysis 1.1).
Moderate to severe pain during procedure
The trial of Rogstad 1992 found that women who received local
anaesthetic reported significantly less moderate or severe pain dur-
ing treatment than women who received control (RR 0.36; 95%
CI 0.18 to 0.71) (Analysis 1.2).
Local anaesthetic plus vasoconstrictor versus control
Three trials (Duncan 2005; Lee 1986; Sammarco 1993) reported
comparisons of local anaesthetic with vasoconstrictor versus con-
trol, but variations in both the interventions or control groups, or
both, meant that the trials were unable to be pooled in a meta-
analysis.
Pain scores during procedure
Meta-analysis of two trials (Lee 1986; Sammarco 1993), assessing
95 women, found that women who received local anaesthetic with
vasoconstrictor (prilocaine 3% with felypressin 0.03 IU/mL and
lignocaine 1% with adrenaline 1:100,000 dilution in the trials of
Lee 1986 and Sammarco 1993, respectively) had significantly less
pain during treatment than women who received no treatment
(MD -23.73; 95% CI -37.53 to -9.93) (Analysis 2.1). The per-
centage of the variability in effect estimates that is because of het-
erogeneity rather than chance may represent substantial hetero-
geneity (I2 = 63%). In trial of Sammarco 1993 women in both
intervention arm and control arm received oral analgesic ketopro-
fen 75 mg single dose within one hour of receiving treatment.
Moderate or severe pain during procedure
Two trials (Duncan 2005; Lee 1986) reporting pain relief with
local anaesthetic plus vasoconstrictor versus control using VRS
showed contrasting results. The trial of Duncan 2005 found that
women who received local anaesthetic with vasoconstrictor (5-mL
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vials of prilocaine 3% (30 mg/mL) with felypressin 0.03 IU/mL)
reported significantly less moderate or severe pain during treat-
ment thanwomenwho received placebo. The Lee 1986 trial found
no statistically significant difference in the same outcome between
women who received vasoconstrictor with local anaesthetic (2 mL
of prilocaine 3% with felypressin 0.03 IU/mL) and those who
received no treatment (RR 0.12; 95% CI 0.04 to 0.37 and RR
0.73; 95% CI 0.42 to 1.27 (Analysis 2.2) for local anaesthetic
with vasoconstrictor versus placebo or no treatment, respectively).
Whether the difference could be attributable to varying dosage of
anaesthetic agents (5 mL in Duncan 2005 trial versus 2 mL in
Lee 1986 trial) is worth considering. No other trials on optimal
dosage have been identified to address this issue. Also of note, the
method of cervical treatment differed in these two trials. Women
in Lee 1986 received cervical treatment with laser vaporisation
while in Duncan 2005 trial the women received treatment with
Semm coagulator (high-temperature electro-cautery).
Haemorrhage (subjective blood loss) during procedure
The trial of Lee 1986 found no statistically significant difference
in the risk of troublesome bleeding between women who received
local anaesthetic with vasoconstrictor (2mL of prilocaine 3%with
0.03 IU/mL of felypressin 0.03 IU/mL) and those who received
no treatment (RR 0.40; 95% CI 0.09 to 1.87) (Analysis 2.3).
However, the blood loss was not measured and was a subjective
impression by the operator.
Local anaesthetic plus vasoconstrictor versus local
anaesthetic injection alone
Moderate or severe pain during procedure
The trial of Diakomanolis 1997 found no statistically significant
difference in the risk of moderate or severe pain between women
who received local anaesthetic with vasoconstrictor (30 mL of a
1:30 ornipressin-lignocaine 1% solution) and those who received
local anaesthetic (30 mL of lignocaine 1% solution) alone (RR
1.20; 95% CI 0.57 to 2.52) (Analysis 3.1).
Haemorrhage (measured blood loss) during procedure
The trial of Diakomanolis 1997 found that women who received
vasoconstrictor (ornipressin 1:30) with local anaesthetic (30mL of
lignocaine 1%) had significantly less measured blood loss during
treatment than women who received local anaesthetic (30 mL
of lignocaine 1%) alone (MD -8.75; 95% CI -10.43 to -7.07)
(Analysis 3.2). In this trial the amount of solution used for cervical
injection of 30mL is higher thanwhat is generally used.Unlike the
subjective evaluation of blood loss in other trials by the operator,
trial of Diakomanolis 1997 reported the actual measured volume
of blood loss.
Speed of procedure (duration of treatment)
The trial of Diakomanolis 1997 found that duration of treatment
was significantly less in women who received vasoconstrictor with
local anaesthetic (30 mL of a 1:30 ornipressin with lignocaine 1%)
than women who received control (30 mL of lignocaine 1%) (MD
-7.72; 95% CI -8.49 to -6.95) (Analysis 3.3).
Local anaesthetic plus vasoconstrictor (prilocaine
(local anaesthetic) with felypressin (vasoconstrictor)
versus lignocaine (local anaesthetic) with adrenaline
(vasoconstrictor))
The trial of Howells 2000 compared two types of local anaesthetic
with vasoconstrictor. More specifically, it reported a comparison
of prilocaine 3% with felypressin 0.03 IU/mL versus lignocaine
2% with adrenaline 1:80,000.
Pain scores during procedure (using 6-point categorical
scale)
The trial found no statistically significant difference in pain scores
when measured using a 6-point categorical scale between women
who received prilocaine and felypressin and those who received
lignocaine and adrenaline (MD -0.05; 95% CI -0.26 to 0.16)
(Analysis 4.1).
Blood loss during procedure
The trial found that women who received prilocaine and fely-
pressin had more mean blood loss during treatment than women
who received lignocaine and adrenaline (MD 0.41; 95% CI 0.13
to 0.69) (Analysis 4.2). However, the observed difference is un-
likely to be clinically significant and the assessment of blood loss
was by subjective scoring and not the actual measured loss.
Deep plus superficial versus deep cervical injection
Pain scores during procedure (VAS: 0 to 100)
The trial of Winters 2009 found no statistically significant differ-
ence in pain scores when measured using a VAS between women
who received deep and superficial injection and those who re-
ceived deep cervical injection (MD -4.90; 95% CI -11.51 to 1.71)
(Analysis 5.1).
Oral analgesic versus placebo or no treatment
Two trials (Al Kurdi 1985; Frega 1994) reported a comparison of
naproxen sodium 550 mg tablets given at least 30 minutes before
treatment (oral analgesic) versus placebo. The trial of Frega 1994
also included a third arm, which had randomised women to no
drug.
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Pain scores during procedure
Meta-analysis of the two trials (Al Kurdi 1985; Frega 1994), assess-
ing 129women, found no statistically significant difference in pain
scores when measured using a VAS between women who received
oral analgesic and those who received placebo (MD -3.51; 95%
CI -10.03 to 3.01 (Analysis 6.1). The percentage of the variabil-
ity in effect estimates that is because of heterogeneity rather than
sampling error (chance) was not important (I2 = 0%). The trial
of Frega 1994 also found no significant difference in pain scores
between oral analgesic versus no treatment (MD -4.00; 95% CI -
13.69 to 5.69 (Analysis 6.1).
Moderate to severe pain during procedure
The trial of Al Kurdi 1985 found no statistically significant dif-
ference in the moderate or severe pain experienced during treat-
ment between women who received oral analgesic and those who
received placebo (RR 0.82; 95% CI 0.60 to 1.13) (Analysis 6.2).
Pain relief required in first 24 hours
The trial of Al Kurdi 1985 found that women who received oral
analgesic for pain relief during colposcopy were significantly less
likely to use additional pain relief within the first 24 hours follow-
ing treatment than women who received placebo (RR 0.12; 95%
CI 0.03 to 0.47) (Analysis 6.3).
Inhalation analgesia versus placebo or no treatment
The trial of Cruickshank 2005 reported a comparison of a gas
mixture (isoflurane and desflurane) as inhalation analgesia versus
placebo (air).
Pain scores during procedure
Cruickshank 2005 found that women who received trial gas mix-
ture for pain relief (in addition to standard cervical injection
with prilocaine 30 mg/mL plus felypressin 0.03 IU/mL) had sig-
nificantly less pain during treatment than women who received
placebo (MD -7.20; 95% CI -12.45 to -1.95) (Analysis 7.1).
Haemorrhage during procedure
Cruickshank 2005 found no statistically significant difference in
the risk of heavy vaginal bleeding between women who received
gas mixture and those who received placebo (RR 1.17; 95% CI
0.83 to 1.64) (Analysis 7.2).
Anxiety (HAD score) during procedure
Cruickshank 2005l found no statistically significant difference in
anxiety scores betweenwomen who received gas mixture and those
who received placebo (MD 0.01; 95% CI -0.80 to 0.82) (Analysis
7.3).
Topical application versus placebo
Four trials (Connell 2000; Lipscomb 1995; Mikhail 1988; Sarkar
1993) reported comparisons of anaesthetic topical application ver-
sus placebo, but variations in the interventions meant that the tri-
als were unable to be pooled in meta-analysis.
Pain scores during procedure
The trial of Lipscomb 1995 found no statistically significant dif-
ference in pain scores whenmeasured using aVAS betweenwomen
who received anaesthetic topical application (20% benzocaine gel)
and those who received placebo (MD -9.00; 95% CI -68.59 to
50.59) (Analysis 8.1). Women in both intervention and placebo
arm received preprocedure oral analgesia in addition to injecting a
total of 4mL of lignocaine 1% (mixed with adrenaline 1:100,000)
in four quadrants of the cervix.
Speed of procedure (duration of treatment)
The trial of Sarkar 1993 found no statistically significant differ-
ence in the duration of treatment between women who received
anaesthetic topical application (EMLA cream - mixture of ligno-
caine 2.5% and prilocaine 2.5%) and those who received placebo
(MD 0.10; 95% CI -1.38 to 1.58) (Analysis 8.2).
Cocaine spray versus placebo
The trial of Mikhail 1988 reported a comparison of cocaine spray
versus placebo.
Pain scores during procedure (VAS: 0 to 100)
The Mikhail 1988 trial found that women who received cocaine
spray for pain relief had significantly less pain during treatment
than women who received placebo (MD -28.00; 95% CI -37.86
to -18.14) (Analysis 9.1).
Moderate to severe pain during procedure
The Mikhail 1988 trial found that women who received cocaine
spray experienced significantly less moderate or severe pain during
treatment than women who received placebo (RR 0.57; 95% CI
0.37 to 0.89) (Analysis 9.2).
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Haemorrhage during procedure (troublesome bleeding)
The Mikhail 1988 trial found that women who received cocaine
spray had significantly less risk of troublesome bleeding following
treatment than women who received placebo. No women in the
cocaine spray arm and 11 out of 25 in the placebo arm had trou-
blesome bleeding. We did not calculate the RR; the default zero-
cell correction within RevMan would bias the result of the meta-
analysis towards no difference between cocaine spray and placebo
(Analysis 9.3).
TENS, local anaesthetic and TENS plus local
anaesthetic injection
The trial of Crompton 1992 reported comparison of TENS,
TENS plus cervical infiltration with local anaesthetic with a vaso-
constrictor (2mL of lignocaine 2% plus octapressin) injection and
local anaesthetic injection alone. As results of pain relief were re-
ported as median with interquartile range, they were not included
in analysis but were summarised separately.
Troublesome blood loss during procedure
The Crompton 1992 trial found no statistically significant differ-
ence in the risk of troublesome vaginal bleeding between women
who received TENS, TENS plus local anaesthetic and local anaes-
thetic alone (RR 2.56; 95% CI 0.28 to 23.29; RR 0.77; 95% CI
0.19 to 3.20 and RR 0.30; 95% CI 0.04 to 2.55 for comparisons
of TENS versus TENS plus local anaesthetic, TENS versus lo-
cal anaesthetic alone and TENS plus local anaesthetic versus lo-
cal anaesthetic alone, respectively) (Analysis 10.1; Analysis 11.1;
Analysis 12.1).
Studies and analyses included within the review but
not in the forest plots
Pain scores (VAS and objective pain scores)
The trials of Connell 2000; Crompton 1992; and Johnson 1996
reported pain scores on VAS scales using median and interquartile
range. The trial of Johnson 1996 also reported objective pain scores
by attending nurse and colposcopist.
Lignocaine spray versus placebo
The trial of Connell 2000 comparing 0.5 mL of lignocaine 10%
spray in addition to standard cervical infiltration with prilocaine
30 mg/mL plus felypressin 0.03 IU/mL versus placebo. The trial
reported the results of pain relief using a VAS scale as median and
interquartile range. The results showed that application of ligno-
caine spray had no significant effect on pain scores (P = 0.38). The
medians with interquartile range of the VAS scale for lignocaine
spray versus placebo were 40.0 (21.25 to 63.25) and 36.0 (17.5
to 49.5), respectively.
TENS, local anaesthetic injection and TENS plus local
anaesthetic injection
The trial of Crompton 1992 reported comparison of TENS,
TENS plus cervical infiltration with 2 mL of lignocaine 2% plus
octapressin and cervical infiltration with cervical infiltration with
2 mL of lignocaine 2% plus octapressin alone.
The results of pain relief using VAS were reported as median pain
scores and interquartile range (24 (10 to 42), 17 (7 to 30) and
18(8 to 31) for TENS, local anaesthetic and TENS plus local
anaesthetic, respectively). The median pain score for the group
assigned TENS only was higher than the median score for the
group given direct infiltration of local anaesthetic (U = -1.57; P =
0.12).
Paracervical versus intracervical injection in the
transformation zone (TZ) of cervix with lignocaine
The trial of Johnson 1996 compared direct infiltration in the TZ
with 2 mL of lignocaine 2% versus paracervical block with ligno-
caine 2% using 5 mL on each side of the cervix. This trial reported
pain relief on a VAS expressing inmedian and interquartile ranges.
The median linear analogue pain scores (interquartile range) for
direct infiltration and paracervical blocks were 14% (6% to 29%)
and 30% (21% to 47%), respectively (Mann-Whitney Z = 2.79;
P = 0.005) suggesting direct infiltration was associated with lower
pain scores. The trial also reported objective pain scores as scored
by attending nurse and colposcopist. The objective pain score
for direct injection with local anaesthetic was slightly lower (23
women; 0 (0 to 0.25)) than the score associated with paracervical
lignocaine injection (21 women; 0 (0 to -0.75); Mann-Whitney
test Z = 0.23; P = 0.8).
D I S C U S S I O N
Summary of main results
Seventeen RCTs (1567 women) met the inclusion criteria and
were assessed in the review. These trials compared a variety of
interventions aimed at reducing pain in women who underwent
treatment for CIN in colposcopy clinic settings, including cervical
injection with lignocaine alone, lignocaine with adrenaline, prilo-
caine with felypressin, oral analgesics (NSAID), inhalation anal-
gesia (gas mixture of isoflurane and desflurane), lignocaine spray,
cocaine spray, local application of benzocaine 20% gel, EMLA
cream and TENS.
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Use of lignocaine 2% for cervical injection (as direct injection or
paracervical block) showed no overall benefit in pain relief as com-
pared to placebo, with one trial (Rogstad 1992) showing a bene-
ficial effect while another trial (Johnson 1989) found no benefit.
Use of the local anaesthetic prilocaine with a vasoconstrictor (fe-
lypressin) showed significant reduction in pain on VAS (Duncan
2005; Lee 1986). However, one trial (Lee 1986) found no benefit
when the pain was assessed with VRS. This trial also reported no
reduction in blood loss with prilocaine plus felypressin. However,
the blood loss was not measured and it was the subjective impres-
sion of the operator. It is also worth noting that this trial (Lee
1986), though randomised, was not a double-blind controlled trial
and only had a small sample size (25 in the intervention arm and
25 in the placebo arm). The addition of a vasoconstrictor agent
(ornipressin) to anaesthetic agent (lignocaine 1%) resulted in sig-
nificantly less measured blood loss and reduction of the duration
of procedure (Diakomanolis 1997). Direct cervical injection with
local anaesthetic (lignocaine 2%) resulted in better pain relief than
placebo (Rogstad 1992) and paracervical block (Johnson 1996).
Superficial injection of local anaesthetic in the cervix before deep
injection did not result in any better pain relief (Winters 2009).
Oral analgesia with an NSAID before the procedure did not result
in better pain relief, although one trial (Al Kurdi 1985) reported
that the women were significantly less likely to use oral analgesics
at home within the first 24 hours of treatment.
Inhalation of gas mixture (isoflurane and desflurane) in addition
to standard cervical injection with prilocaine 30 mg/mL plus fe-
lypressin 0.03 IU/mL resulted in significantly less pain during the
LLETZ procedure with no effect on blood loss or HAD anxiety
scores (Cruickshank 2005).
EMLA local anaesthetic cream did not result in better pain relief
compared to placebo (Sarkar 1993). Spraying of the cervix with
cocaine spray before treatment resulted in better pain relief and
less troublesome bleeding (Mikhail 1988). Use of topical gel (ben-
zocaine 20%) (Lipscomb 1995) or lignocaine spray in addition to
standard cervical injection prilocaine 30 mg/mL plus felypressin
0.03 IU/mL did not result in any benefit (Connell 2000).
On comparisonof different preparations of local anaestheticmixed
with vasoconstrictor, prilocainewith felypressin did not differ from
lignocaine with adrenaline for its effect on pain control (Howells
2000). Mean observed blood loss was less in the lignocaine with
adrenaline group comparedwith prilocaine with felypressin group,
although the difference was not clinically significant.
The use of TENS on its own or combined with local anaesthetic
injection during cervical laser therapy did not appear to be of any
benefit (Crompton 1992).
No serious side effects were noticed in the trials reporting these
outcomes. The reported side effects were feeling faint, shaking,
dizziness, abdominal cramps, sweating, feeling hot, weakness,
and moderate, transient hypertension. Prilocaine with felypressin
caused fewer side effects (mainly shaking and fainting) than lig-
nocaine with adrenaline in one trial (Howells 2000).
Overall completeness and applicability of
evidence
This review consists of many single trial analyses of small numbers
of women, which limits the conclusions that can be drawn. Some
of the trials included use of more than one type of pain relief inter-
vention such as preoperative oral analgesics in addition to cervical
infiltration. In modern day colposcopy practice, commonly used
interventions for pain relief are local anaesthetic infiltration with
vasopressin followed by large loop excision of the cervix, cryother-
apy, laser ablation or conisation with a knife. In order to improve
quantification of the benefits of these interventions in relief of pain
and other symptoms (blood loss, etc.) without significant side ef-
fects, larger RCTs are required.
Measurement of pain
Several validated scales were used for the measurement of pain
in the trials included within the review, which may influence the
accuracy of the outcome as complexity of the rating task for the
measure influences the sensitivity and specificity. It is thought
that a VAS reflects pain experienced during operative procedures
more accurately (Huskisson 1983). VAS were used to report pain
relief in 13 of the included trials (Al Kurdi 1985; Connell 2000;
Cruickshank 2005; Frega 1994; Johnson 1989; Johnson 1996; Lee
1986; Lipscomb 1995; Mikhail 1988; Rogstad 1992; Sammarco
1993; Sarkar 1993;Winters 2009). Sammarco 1993 reportedVAS
using an 11-point scale. In addition to VAS, two trials (Johnson
1989; Johnson 1996) also reported pain relief as an objective score
given by the attending nurse and laser operator on a categorical
scale of 0 to 2. In the other trial (Howells 2000), pain was scored
by the attending colposcopist on a categorical scale (0 to 4) as well
as by women undergoing treatment (0 to 5). Sarkar 1993 reported
pain utilising McGill’s pain questionnaire, on a categorical scale to
grade pain, cramp and backache caused by the laser treatment. In
five trials (Al Kurdi 1985; Diakomanolis 1997; Duncan 2005; Lee
1986; Mikhail 1988) pain relief was reported on VRS categorised
as none, mild, moderate or severe.
An element of under reporting has been demonstrated, especially
where specific mean and SDs have not been stated. Several trials
reported pain as a graphical representation without numerical val-
ues, which is a form of under reporting. Such selective outcome
reporting must be taken into consideration when interpreting the
results. The trials of Johnson 1996, Connell 2000 and Sarkar 1993
reported pain relief as VAS, but the values were median and in-
terquartile range rather than mean and SD and therefore these
data could not be converted to mean pain scores. In four trials
(Frega 1994; Lee 1986; Mikhail 1988; Rogstad 1992), pain relief
outcomes were reported as a graphical representation that required
calculation of mean and SD. In three trials (Frega 1994; Mikhail
1988; Lee 1986), graphical representation of data was without nu-
merical values. The major limitation of the review and interpreta-
tion of the results is the presence of selective outcome reporting.
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Quality of the evidence
This review incorporates evidence from 17 RCTs that assessed
1567 women in total. Effective pain relief from local anaesthesia
is dependent on various factors, including route of administra-
tion, concentration and classification of drug, and the time inter-
val between the administration of the analgesic and start of the
procedure. These factors differed between the trials. This review
was unable to establish the time interval between administration
of injection and start of the procedure from the trial data.
Owing to the heterogeneity of the outcomes and treatments con-
sidered, there are many single trial analyses and limited consistent
data available to carry out comparisons between trials. The major-
ity of the included trials were underpowered to demonstrate a sig-
nificant effect and some trials did not include a power calculation
in their methodologies. As the majority of comparisons relied on
single trials that were underpowered, the treatment effects should
ideally be examined by conducting further studies.
Potential biases in the review process
A comprehensive search was performed, including electronic
databases and a thorough search of the grey literature. All refer-
ences were sifted and data extracted by two review authors in-
dependently. We restricted the included studies to RCTs as they
provide the strongest level of evidence available. Hence, we have
attempted to reduce bias in the review process.
The greatest threat to the validity of the review is likely to be the
possibility of publication bias (i.e. studies that did not find the
treatments to have been effective may not have been published).
We were unable to assess this possibility as the meta-analyses in-
cluded a limited number of the included trials (two out of 17 in-
cluded trials).
Agreements and disagreements with other
studies or reviews
These found no other systematic reviews in this field and we did
not identify any other retrospective controlled studies using these
outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Oral analgesia, EMLA cream, TENS, lignocaine spray or benzo-
caine gel did not provide any benefit in pain relief during cervical
colposcopy treatment. Spraying of cervixwith cocaine spray before
treatment resulted in better pain relief and also less troublesome
bleeding. Local anaesthetic agent combined with a vasoconstrictor
agent resulted in better pain control compared with placebo and
was associated with significantly less blood loss. Mean observed
blood loss score was less with lignocaine plus adrenaline as com-
pared with prilocaine plus felypressin, although the difference was
not clinically significant. Direct cervical injection of local anaes-
thetic with a vasoconstrictor agent resulted in reduction in pain
scores during treatment and should be considered for all cervical
colposcopy treatment for CIN. However, no conclusions can be
drawn with regards to optimum number of sites to inject in the
cervix, depth of injection in the cervix (superficial, deep, or both)
and dosage of the agent used. In terms of side effects, combina-
tion of prilocaine with felypressin caused fewer side effects than
lignocaine with adrenaline. Inhalation of gas mixture in addition
to standard pain relief injection appears to have additional pain
relief benefit. In routine clinical practice, intracervical injection
of analgesic with a vasoconstrictor, particularly those related to
vasopressin, appeared to be the optimum analgesia for treatment.
Implications for research
Oral analgesia and the individual topical agents such as EMLA
cream, lignocaine spray or benzocaine gel appeared to provide
little benefit over placebo or no treatment for pain relief during
colposcopy. However, this evidence comes from small trials with
methodological shortcomings, therefore we consider this evidence
to be of a low quality.
Further available evidence suggests that a local anaesthetic com-
bined with a vasoconstrictor agent significantly reduces pain and
measured blood loss, therefore this treatment should be offered
to women undergoing colposcopy. This evidence is of moderate
quality and further research will have an important impact on our
confidence in these findings.
Further high-quality, adequately powered trials should be under-
taken in order to provide the data necessary to estimate the opti-
mal route of administration and dose of local anaesthetics.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Al Kurdi 1985
Methods Prospective randomised double-blind trial
Single centre
Participants 97 women satisfied the inclusion criteria and were entered into the study. 50 were allotted
naproxen sodium treatment and 47 were given a placebo. Women were generally healthy
and undergoing CO2 laser treatment for CIN for the first time. Pregnancy, lactation, a
history of bronchial asthma or allergic diathesis, and concomitant use of highly protein
bound drugs excluded women from entry to the trial. All women were assessed following
laser treatment but 2 women from the naproxen sodium group failed to return their 24-
hour questionnaire
Age 18 to 50 years
3 women from each group failed to complete their laser treatment because of pain
and were subsequently given local or general anaesthetics. Their response to the laser
treatment was recorded and included in the analysis
Interventions 2naproxen sodium550mgor 2placebo tabletswere givennot less than30minutes before
theCO2 laser treatment of the cervixwas performed. Almost always the procedure started
within 60 minutes of taking the tablets. Laser treatment was performed as previously
described (Lowles 1983) and the duration of laser treatment and laser working time were
recorded
Outcomes VAS: a 10-cm VAS, which ranged from no pain to the
worst pain ever experienced by the patient
Pain intensity was measured using both a VAS and VRS (none, very slight, mild, mod-
erate, severe)
Speed of procedure reported as total treatment time
Various other outcomes not specified in our protocol
Notes Analgesic use following treatment (in the naproxen sodium group only 2 out of 48
women used analgesics compared to 17 out of 47 women in the placebo group)
Self-reported side effects were very minor (aches and pains at 24 hours) and not included
in analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Unclear risk Not reported
Allocation: sequence concealment Unclear risk Not reported
Performance and detection: blinding
All outcomes
Unclear risk Not reported
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Al Kurdi 1985 (Continued)
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 97/97 (100%) women were
analysed for pain. 2 women in treatment
armdidnot reply to 24-hour questionnaire,
but we assessed women immediately after
treatment to eliminate recall bias
Reporting: unreported outcomes Low risk Pertinent outcomes were reported in the
trial
Other: anything else Low risk No additional form of bias was likely
Connell 2000
Methods Prospective, randomised, double-blind, placebo-controlled study
Setting: colposcopy clinics at teaching hospital
Participants Women aged 20 to 64 years who were undergoing biopsy or loop excision under local
anaesthetic for cytological abnormalities were recruited to the study. Of the 51 women
entered into the study, 19 had a biopsy performed and were excluded from analysis. 32
had a LLETZ and were included for analysis. 16 were randomised to receive solution A
(lignocaine spray) and 16 had solution B (saline). 2 women in group failed to complete
the second VAS so effectively 30 women were included in the final analysis - 15 in each
of 2 groups
Interventions Women were randomised to receive either the lignocaine hydrochloride 10% spray
or saline. Multiple atomiser bottles were made up with solution and were labelled ’A’
or ’B’. The spray was primed and the operator depressed the spray 4 times applying
approximately 0.5 mL of solution to the cervix. At least 1 minute later 1.1 mL of
local anaesthetic (prilocaine hydrochloride 30 mg/mL with felypressin 0.54 µg/mL) was
injected with a dental syringe and needle. In the LLETZ group injection was into 4
quadrants, the total volume being 4.4 mL
Outcomes Pain was measured using 100-mm VAS score. The woman was asked to mark the line
with a cross as soon as the injections had been performed. Pain was also assessed with a
4-point categorical scale: 1 = not painful; 2 = slightly painful; 3 = moderately painful; 4
= severely painful
Notes Pain was only reported on VAS. The outcome reported on categorical scale was not
included in the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
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Connell 2000 (Continued)
Allocation: sequence generation Low risk “Randomisation was by stratified com-
puter-generated numbers”
Allocation: sequence concealment Low risk To ensure blinding, the bottles were made
up in the pharmacy department who also
sealed the code in an envelope
Performance and detection: blinding
All outcomes
Low risk The attending doctor, the nursing staff,
the woman and the investigator were all
blinded to the identification of the solution
used
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 94% (30/32) analysed for all
outcomes
Reporting: unreported outcomes High risk Blood loss and duration of procedure was
not reported. The outcome for categorical
scale of pain relief was not available to carry
out comparison
Other: anything else Low risk No additional risk of bias was likely
Crompton 1992
Methods Prospective randomised 3-arm controlled clinical trial
Setting: colposcopy unit adapted to run randomised trials
Participants 100 women with a colposcopic diagnosis of CIN were recruited. They had a gynae-
cological interview, colposcopy and a colposcopically directed biopsy. Linear analogue
anxiety and HAD anxiety/depression personality trait scores (Zigmond 1983), age and
number of vaginal deliveries were recorded to assess group comparability. Women who
had a past history of treatment for CIN, other cervical surgery or pelvic inflammatory
disease, postmenopausal women and women with cardiac pacemakers were excluded. 2
other women refused to enter the trial
Mean (SD) age at trial entry: TENS only: N = 34, 31.8 years (SD = 9); local anaesthetic:
N = 35, 32.6 years (SD = 9); TENS and local anaesthetic: N = 29, 30.1 years (SD = 8)
% of women who were nullipara: TENS only: 48%; local anaesthetic: 44%; TENS plus
local anaesthetic: 35%
Median anxiety HAD score (interquartile range): TENS only: 6 (5 to 11), local anaes-
thetic: 7 (4 to 9), TENS plus local anaesthetic: 6.5 (4 to 8)
Median depression HAD score (interquartile range): TENS only: 3 (1 to 4), local anaes-
thetic: 2 (1 to 4), TENS plus local anaesthetic: 3 (1 to 3)
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Crompton 1992 (Continued)
Interventions Subjects were allocated to 1 of 3 groups: (1) TENS (N = 34), (2) TENS plus direct
infiltration of 2 mL lignocaine 2% plus octapressin 1:10,000 (0.03 IU/mL) (N = 29)
and (3) direct infiltration of 2 mL 2% lignocaine plus octapressin (N = 35). A total
of 2 mL of lignocaine 2% + octapressin was injected from a dental syringe via a 30-
gauge needle into 4 points on the TZ to a depth of 3 to 5 mm. Microtens TENS
pads (Neen Pain Management Systems, Norfolk, UK) were applied 20 minutes before
treatment. 4 conductive silicone polymer electrodes were applied using conducting gel
and tape fixative; 2 anterior to the abdominal wall just above the symphysis pubis and 1
on each side of the sacrum. The electrodes were connected to an 80-Hz nerve stimulator
(pulse width 210 µs) by a cable. The single channel amplitude control was activated by
the patients under instruction. Initially they were encouraged to experience a tingling
sensation and then they increased the amplitude until it became uncomfortable. They
were given approximately 20 minutes to experiment with the device until they were
called into the second room for laser treatment. All the treatments were carried out in
this second room by a second operator. The entire ectocervical TZ was either ablated to
a depth of approximately 7 mm or excised with the aid of skin hooks using a 35-W CO2
laser (spot size 1.5 mm)
Outcomes At the end of the procedure the surgeon gave a further explanation of the treatment and
scored the pain experienced by the patient using 120-mm visual linear analogue scores.
The scores were converted into percentages
At the end of the procedure the women offered TENSwere given a simple questionnaire.
They were asked to answer ’Yes’ or ’No’ to indicate whether or not they found the TENS
each of the following: (1) comfortable, (2) unpleasant, (3) helpful, (4) frightening, (5)
soothing or (6) pain relieving
Notes Median pain score was on 120-mm VAS; however, authors converted it to percentage
for reporting
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Unclear risk Not reported
Allocation: sequence concealment High risk “The block randomisation code was held
by one investigator who then allocated
treatment”
Performance and detection: blinding
All outcomes
High risk “It was impossible to conceal the use of
TENS from the surgeon and patients but
we had intended to ’blind’ the attendants
to the use of local anaesthesia. Injections
of lignocaine were given in a separate room
before the laser surgery was carried out by
a different attendant but the surgeon was
able to identify points where local anaes-
thetic had been given”
22Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Crompton 1992 (Continued)
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 98% (98/100) analysed for all
outcomes
Reporting: unreported outcomes Unclear risk Median pain scores reported rather than
mean and adverse events were not reported
Other: anything else Unclear risk Insufficient information to permit judge-
ment
Cruickshank 2005
Methods Prospective double-blind RCT
A colposcopy clinic serving a regional population in single-centre setting
Participants 396 women scheduled for treatment of CIN by LLETZ. All women attending for in-
vestigation of an abnormal smear were screened and women suitable for treatment at
their first visit (’see and treat’). Most women were seen for initial colposcopic assessment
with directed punch biopsies only and treatment at a later appointment if necessary.
Women were excluded if treatment was deferred because of pregnancy, if they were cur-
rently taking a monoamine oxidase inhibitor or if they had to drive home from the clinic
themselves
Mean age at trial entry was 32.7 years (SD 9.8) and 31.5 (SD 9.1) in the isoflurane plus
desflurane and placebo arms, respectively
Deprivation score details were as follows:
Class 1 (least deprived): 82 (82/395, 20.7%); Class 2: 72 (18.2%); Class 3: 53 (13.4%)
; Class 4: 37 (9.4%); Class 5: 36 (9.1%); Class 6: 16 (4.0%); Class 7: 46 (11.6%); not
classified: 53 (13.4%)
Parity details were as follows: no children: 158 (40.3%), 1 to 5 children: 234 (59.7%)
Interventions The intervention was a mixture of isoflurane and desflurane gases (N = 195) versus
placebo (air) (N = 194). Both gases were self-administered by the women using a demand
valve regulator (Ohmeda) as is used for Entonox. The slight odour of the trial gas was
masked by a small amount of peppermint oil smeared inside the facemask for trial
and control gas administration. The women were instructed to use the gas before the
procedure began and to continue to use the gas according to their own requirements.
Exhaled gas was scavenged using standard equipment (Ohmeda). Infiltration of the
cervix with prilocaine hydrochloride (30 mg/mL) and octapressin (0.54 mg/mL) was
started approximately 2 minutes after the start of inhalation. 2 to 3 ampoules were used
at the clinical discretion of the colposcopist depending on the size of the cervical lesion.
A number of different colposcopists performed treatment and were evenly distributed
between the 2 arms
Outcomes Pain measured using VAS (0 to 100 where 100 was worst pain imaginable)
Heavy vaginal bleeding
Anxiety using HAD
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Cruickshank 2005 (Continued)
Various other outcomes not specified in our protocol
Notes Women were followed up immediately after colposcopy and at 6 months after. We did
not report 6 month data as recall bias was likely to be a problem
“Took pain killer for stomach pain” - this outcome did not mention the time limit from
procedure and so it was excluded from analysis (intervention group: 66/175; comparison
group: 66/173)
9/175 and 7/173 women had difficulty returning to normal activity after colposcopy in
intervention and placebo groups, respectively
14/175 and 15/173 women contacted on-call service with problem related to treatment
in intervention and placebo groups, respectively
These 2 outcomes were not included in forest plots since descriptions were vague and
full details were not provided
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Low risk “The random allocation of women to
the cylinder code used computer-generated
random numbers”
Allocation: sequence concealment Low risk “The random allocation of women ... used
... a series of opaque sequentially numbered
envelopes”
Performance and detection: blinding
All outcomes
Low risk “The trial and clinic staff and trial partic-
ipants were blinded to the contents of the
cylinders, and peppermint oil was applied
to the facemask prior to use”
Detection: blind outcome assessment
All outcomes
Low risk “The subject matter was tabulated by an as-
sessor blinded to the randomisation of each
individual”
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 348/395 (88%) for heavy vagi-
nal bleeding outcome. Other outcomes as-
sessedmore than 88%ofwomen in the trial
Reporting: unreported outcomes High risk Adverse events of gas were not reported
Other: anything else Low risk No additional form of bias was likely
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Diakomanolis 1997
Methods Randomised double-blind study
Single centre
Participants 100 women were randomly allocated to 1 of 2 groups. All underwent laser excision of
TZ for CIN. All women included in the study had abnormal Pap smears. Abnormal
colposcopic findings, histologically confirmed CIN and were premenopausal. All women
with history of coronary disease, epilepsy and chronic hypertension were excluded from
the study
Median age of patient in Group A (vasoconstrictor + lignocaine) 28 years (range 17 to
50)
Median age of patient in Group B (lignocaine only) 28.5 years (range 19 to 51)
Interventions Group A vasoconstrictor + lignocaine) consisted of 50 women who underwent laser
excision using 30 mL of a 1:30 POR8 (vasoconstrictor) + lignocaine 1% solution The
ectocervix was infiltrated with solution just before the start of procedure using a 30-
gauge dental needle on a dental syringe to a depth of 3 to 4 cm
Group B (lignocaine only) consisted of 50 women who underwent laser excision received
30 mL of lignocaine 1% solution without POR8 - vasoconstrictor
Outcomes The intraoperative blood loss was measured with a glass blood measure (maximum
volume 60 mL) (used in paediatric surgery) set in the suction apparatus
Postoperative haemorrhage was measured with weighing the blood that soaked the pads
Early haemorrhage was defined as bleeding occurring within 4 days of operation that
requires intervention to stop bleeding. Late haemorrhage was after 4 days
Pain relief was recorded as VRS (none, moderate and severe) postoperatively
The operative time of each procedure was recorded. After the procedure, all women were
contacted by telephone 1 week later
Notes Other outcomes were not included in analysis like hypertension. Hypertension was seen
in 7 women in Group A (vasoconstrictor + lignocaine) while in 2 women in Group B
(lignocaine only)
Note: the 30 mL of local anaesthetic with vasoconstrictor or local anaesthetic alone
is considered a higher than average amount used to infiltrate cervix in pain relief for
colposcopic management
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Unclear risk Not reported
Allocation: sequence concealment Low risk “The randomization was performed as the
central pharmacy of the hospital during the
preparation and distribution of both med-
ications used”
Performance and detection: blinding
All outcomes
Low risk “The surgeon was not aware of the medi-
cation that was used”
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Diakomanolis 1997 (Continued)
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 100/100 (100%) analysed for
all outcomes
Reporting: unreported outcomes High risk Pain was not analysed using VAS
Other: anything else Unclear risk An additional form of bias was unlikely
Duncan 2005
Methods Double-blind randomised prospective placebo-controlled trial
Single centre
Participants Out of 100 women who met the criteria and approached 93 were enrolled in the study.
The numbers of women studied were 46 in intervention arm and 47 in comparison
arm. 100 consecutive women attending the colposcopy clinic and expected to undergo
colposcopically directed biopsy and treatment with Semmcoagulator were approached. 7
did not meet the eligibility criteria. Women with a history of allergy to local anaesthetic,
who are unsuitable for treatment at first colposcopy examination, who had previous
treatment to cervix or were pregnant were excluded
Mean (SD) and/or median (and range) age at trial entry: intervention: N = 46, mean
age = 31.3 years (SD 8.4);
comparison: N = 47, mean age = 32.6 years (SD 8.0)
Nullipara: intervention: 14 women (30.4%); comparison: 10 women (21.3%)
Married/cohabiting: intervention: 20 women (43.5%); comparison: 22 women (46.8%)
CIN (1/2/3/unspecified) details (number (%)):
• intervention: HPV/CIN1 = 17/46 (37%), CIN2,3 = 29/46 (63%), microinvasion
= 0/46 (0%)
• comparison: HPV/CIN1 = 17/47 (36.2%), CIN2,3 = 29/47 (61.7%),
microinvasion = 1/47 (2.1%)
Interventions Externally identical numbered 5-mL vials of prilocaine 3% (30 mg/mL) with felypressin
0.03 IU/mL or normal saline were prepared in-house in pharmacy department along
with randomised opaque sealed envelopes each containing number of vial. Colposcopic
examinations were performed by 1 of the authors. Once treatment decision was taken
vial was opened from sealed envelope and injected circumferentially in TZ of cervix.
Volume was noted. Treatment was performed with SEMM coagulator
Outcomes Pain was recorded on 11-point analogue scale where 0 was no pain at all and 10 indicated
the worst pain imaginable. Each patient was asked to complete 4 such scales: expected
and actual sensation for biopsy and treatment. Pain scores of 1 to 3 were classified as
mild, 4 to 7 as moderate and 8 to 10 as severe
Notes Details of anticipated pain was excluded from the analysis
Risk of bias
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Duncan 2005 (Continued)
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Unclear risk Not reported
Allocation: sequence concealment Low risk “Externally identical, numbered vials of ac-
tive medications or normal saline were pre-
pared by the in house pharmacy depart-
ment alongwith randomised opaque sealed
envelopes, each containing the number of
a vial. Pharmacy retained the key to the vial
contents until the end of the trial”
Performance and detection: blinding
All outcomes
Unclear risk Labelled as double blindplacebo controlled
trial, but details are not documented inma-
terials and methods section
Detection: blind outcome assessment
All outcomes
Unclear risk See above
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 92/93 (99%) of the women
were analysed for pain related to treatment.
Data from 1 patient were missing in the
active drug group
Reporting: unreported outcomes High risk Adverse event were not reported
Other: anything else Low risk An additional form of bias was unlikely
Frega 1994
Methods Randomised study
Participants 63 women affected by CIN of various degrees were randomly divided into 3 groups in
order to evaluate the pain experienced during laser vaporisation of the lesion. All women
were premenopausal and ages ranged between 19 and 39 years. Each group consisted of
21 women
Interventions The first group received naproxen sodium 550 mg 30 minutes before treatment; the
second group received placebo 30 minutes before treatment and the third no drug (21
women in each group)
Outcomes At the end of the procedure, the severity of pain was assessed using 0- to 100-mm VAS
Notes Mean and SD for each group was calculated fromfigure 1 on page 189 of the publication,
using GraphPad Prism software package, where the graphs were enlarged allowing an
accurate estimate of each individuals pain score
Since the trial included 3 arms, the shared intervention group was divided out approxi-
mately evenly among the comparisons. Hence for pain outcome on VAS, the total num-
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Frega 1994 (Continued)
ber of women in the drug group was divided up into 2 (the total number of 21 in the
group was halved and rounded up to 11) and the means and SDs were left unchanged
(see Higgins 2011, chapter 16.5.4)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Unclear risk Not reported
Allocation: sequence concealment Unclear risk Not reported
Performance and detection: blinding
All outcomes
Unclear risk Not reported
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 63/63 (100%) analysed for all outcomes
Reporting: unreported outcomes High risk Median rather than mean used for pain and adverse events were
not reported




Participants 200 consecutive women referred by general practitioners with abnormal cervical cytology
(N = 180) or clinically suspicious abnormality (n = 20) were enrolled Inclusion criteria
for the study were: women aged 20 and 60 years; who had received no previous treatment
to the cervix who require treatment
Mean age (SD) (prilocaine plus felypressin vs. lignocaine plus adrenaline): 94 women;
36.6 years (10.3) vs. 106 women; 34.6 years (9.7)
Menopausal status (prilocaine plus felypressin vs. lignocaine plus adrenaline):
premenopausal: 81 (86%) vs. 96 (91%); postmenopausal: 12 (13%) vs. 9 (8%); missing
data: 1 (1%) vs. 1 (1%)
Contraception (prilocaine plus felypressin vs. lignocaine plus adrenaline): no: 37 (39%)
vs. 44 (42%); yes: 61 (65%) vs. 76 (72%); missing data: 0 vs. 1 (1%)
Smear grade (prilocaine plus felypressin vs. lignocaine plus adrenaline):
• low grade/negative: 35 (37%) vs. 49 (46%)
• high grade: 53 (57%) vs. 51 (48%)
• other grades: 5 (5%) vs. 4 (4%)
Nullipara (prilocaine plus felypressin vs. lignocaine plus adrenaline): 17 (18%) vs. 24
(23%)
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Howells 2000 (Continued)
Colposcopic findings (prilocaine plus felypressin vs. lignocaine plus adrenaline): normal:
13 (14%) vs. 15 (14%); low grade: 25 (27%) vs. 29 (27%); high grade: 49 (52%) vs.
53 (50%); uncertain: 5 (5%) vs. 7 (7%); ? invasion: 1 (1%) vs. 1 (1%); missing data: 1
(1%) vs. 1 (1%)
Final histology (prilocaine plus felypressin vs. lignocaine plus adrenaline): normal: 4
(4%) vs. 8 (8%); low grade: 36 (38%) vs. 31 (29%); high grade: 51 (55%) vs. 63 (59%)
; others: 3 (3%) vs. 2 (2%); missing data: 0 vs. 2 (2%)
Final histologywas negative for (prilocaine plus felypressin vs. lignocaine plus adrenaline)
: 4/94 (4%) vs. 8/106 (8%); exclusion from analysis not possible so included in analysis
Local anaesthetic volume (mL) (prilocaine plus felypressin vs. lignocaine plus adrenaline)
: 5.02 mL vs. 4.83 mL
Loop passes (prilocaine plus felypressin vs. lignocaine plus adrenaline): 1 pass: 71 (76%)
vs. 80 (75%); 2 passes: 19 (20%) vs. 18 (17%); 3 passes: 2 (%) vs. 4 (4%)
Loop size (prilocaine plus felypressin vs. lignocaine plus adrenaline): small: 10 (11%)
vs. 14 (13%); medium: 80 (85%) vs. 87 (82%); large: 3 (3%) vs. 1 (1%); Missing data
(prilocaine plus felypressin vs. lignocaine plus adrenaline): 1 (1%) vs. 4 (4%)
Interventions Intervention group (N = 94) received prilocaine 3% (30 mg/mL) with felypressin 0.03
IU/mL. Comparison group (N = 106) received lignocaine 2% with adrenaline 1:80,000
(xylocaine)
Outcomes The duration of the treatment was calculated from the start of the loop excision to the
end of ball diathermy used to achieve haemostasis
The colposcopist scored his or her perception of the discomfort experienced by the
women in a scale of ordered categories (0 = ’none’; 4 = ’severe’) and also the degree of
bleeding caused by the procedure (0 = ’none’; 5 = ’heavy’)
Following treatment, the women answered a questionnaire on their perception of pain
during the administration of the local anaesthetic and during their treatment in a scale
of ordered categories (0 = ’none’; 5 = ’unbearable’)
Other side effects, such as feeling faint, nausea and shaking, were also scored in a similar
fashion (0 = ’none’; 5 = ’a great deal’). The scores were then added to derive an overall
score
Notes Missing data (prilocaine plus felypressin vs. lignocaine plus adrenaline): 1 (1%)vs. 2
(2%)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Unclear risk “The women were randomised by an inde-
pendent observer using simple randomisa-
tion”
Allocation: sequence concealment Low risk “The women were randomised ... using
simple randomisation with opaque sealed
envelopes”
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Performance and detection: blinding
All outcomes
High risk “The colposcopists were aware of the iden-
tity of the local anaesthetic solutions”
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 200/200 (100%)
Reporting: unreported outcomes High risk Important outcomes were reported by the
trial authors but these could have been
reported using more appropriate methods
(e.g. continuous data for pain and blood
loss, rather than using logistic regression for
non-parametric data)
Other: anything else Low risk No additional form of bias was likely
Johnson 1989
Methods Prospective double-blind randomised placebo-controlled clinical trial
Participants 70 women with a new colposcopic and histological diagnosis of a cervical dysplastic
lesion suitable for laser ablation. The following prospective exclusion criteria were used:
previous cervical surgery, more than 1 colposcopic examination, menopausal or peri-
menopausal status, sensitivity to lignocaine, patient refusing paracervical injection or
refusing to be recruited into the trial, or vaginal involvement of the lesion
Interventions Women were randomised to receive either lignocaine 2% or normal saline from a num-
bered vial. A bilateral paracervical block was delivered by injecting 10 mL into the parac-
ervical tissues
Outcomes At the end of the procedure and after a further explanation, the women scored their
pain on a 120-mm visual linear analogue scale. Pain was also objectively scored by the
attending nurse who assessed the woman’s level of vocalisation (2 = moan/cry; 1 = gasp;
0 = no vocalisation), muscle tension of the upper limbs (2 = the clenching the bed etc.; 1
= making a fist; 0 = relaxed), thigh movements (2 = adduction; 1 = twitchy; 0 = relaxed)
. The laser operator independently scored movements of the thigh as well as perineal
movement (2 = bottommovement up the bed; 1 = speculum twitches; 0 = nomovement/
relaxed). The size of the TZ and blood loss were recorded. Anxiety and depression HAD
scores and premenstrual syndrome scores were also recorded
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Johnson 1989 (Continued)
Allocation: sequence generation Low risk “Consenting patients were then ran-
domised to receive either 2% lignocaine or
normal saline from a numbered vial. Each
vial could only be identified at the end of
the study by its number which was allo-
cated prospectively according to a block
randomised code”
Allocation: sequence concealment Low risk “Each vial could only be identified at the
end of the study by its number which was
allocated prospectively”
Performance and detection: blinding
All outcomes
Low risk Trial was labelled as a placebo-controlled
double-blind trial. “Laser ablation of the
entire transformation zone to a depth of
approximately 7 mm was performed with
a continuous fine beam (spot size 1.5 mm)
35-W CO, laser by a separate surgeon in a
second suite”
Detection: blind outcome assessment
All outcomes
Low risk “Pain was objectively scored by the attend-
ing nurse who assessed the woman’s level of
vocalization ... muscle tension of the upper
limbs, thigh movements ... The laser op-
erator independently scored movements of
the thigh as well as perineal movement”
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 70/70 (100%)
Reporting: unreported outcomes High risk Adverse events of paracervical injections
were not reported and pain was inade-
quately reported
Other: anything else Low risk No additional form of bias was likely
Johnson 1996
Methods Double-blind randomised clinical trial
Colposcopic clinic specifically adapted to run clinical trials
Participants 44 (23 in intervention group and 21 in comparison group) women were recruited from
a laser colposcopy clinic. They were referred following abnormal smear and underwent
colposcopic examination and biopsy before being recruited. No participant refused entry
in the trial but the trial was terminated prematurely when the laser surgeon realised that
he could identify women given direct infiltration by looking for the injection mark. Fol-
lowing exclusion criteria were applied: past cervical surgery, past cervical atypia, vaginal
involvement with lesion, the menopause, reluctance to take part in trial
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Johnson 1996 (Continued)
Interventions This study compared site of injection of the pain relief. Intervention group received
10 mL of paracervical lignocaine 2% while the comparison group received 2 mL of
lignocaine 2% directly into the TZ
Outcomes Pain was scored on VAS at the end of the procedure by the patients. Pain was objectively
scored by the attending nurse and the laser operator independently
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Low risk “Consenting women were block ran-
domised to receive either 10ml of paracer-
vical 2% lignocaine or 2ml of 2% ligno-
caine injected directly into the transforma-
tion zone”
Allocation: sequence concealment Low risk “Neither nurses, clerical officers responsible
for appointments, nor the laser surgeonhad
access to this code. The worker responsible
for randomisation obtained consent, drew
the allocation code from a box”
Performance and detection: blinding
All outcomes
Low risk “Theworker responsible for randomisation
... gave the local anaesthetic in a room sep-
arate from the laser suite”
Detection: blind outcome assessment
All outcomes
Low risk “Pain was objectively scored by the attend-
ing nurse who assessed the woman’s level of
vocalization ... muscle tension of the upper
limbs and thigh movements. The laser op-
erator independently scored movements of
the thigh as well as perineal movement”
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 44/44 (100%)
Reporting: unreported outcomes High risk Adverse events of paracervical injections
were not reported and pain was inade-
quately reported
Other: anything else Unclear risk No woman refused entry to the trial,
but the study was terminated prematurely
when the laser surgeon realised that he
could identify women given direct infiltra-
tion by looking for the injection marks. Up
to this point, the study was a true double-
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blind, randomised trial. This is not neces-
sarily a source of bias but we were unsure




Participants 50 women undergoing laser vaporisation of cervix for CIN were recruited to 1 of the 2
groups. All women were premenopausal and aged 19 to 39 years
Interventions In the intervention group (N=25), the ectocervixwas infiltratedwith 2mLprilocaine 3%
with felypressin 0.03 IU/mL immediately before the procedure, while in the comparison
group (N = 25) women received no analgesia or anaesthesia. Using a 30-gauge dental
needle on a dental syringe, Infiltration around the periphery of the TZ was performed
immediately before the procedure. Local anaesthetic was employed in the control group
only when significant pain was experienced
Outcomes The severity of the pain was assessed at the end of the procedure using VAS and VRS. The
VAS consisted of a 100-mm line drawn on plain paper representing pain ranging from
’no pain at all’ to ’pain as much as you can imagine’. Patients marked a point on the line
at the end of the procedure which they felt corresponded to the pain they experienced.
The VRS consisted of a choice of 4 descriptions, none, mild, moderate or severe. Blood
loss during the procedure was recorded as none, slight, moderate and troublesome
Notes Other outcome measures included pain while receiving the injection and the level of
anxiety before the procedure was measured before the patient undressed using the Spiel-
berger state anxiety inventory. Side effects such as sweating, nausea, dizziness and cramps
were also reported. This was not included in the analysis
Mean and SD for each group was calculated fromfigure 1 on page 968 of the publication,
using GraphPad Prism software package, where the graph was enlarged allowing an
accurate estimate of each individuals pain score
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Unclear risk Not reported
Allocation: sequence concealment Unclear risk Not reported
Performance and detection: blinding
All outcomes
Unclear risk Not reported
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
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Lee 1986 (Continued)
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 50/50 (100%)
Reporting: unreported outcomes Low risk Pertinent outcomes were reported in the trial
Other: anything else Unclear risk No additional form of bias was likely
Lipscomb 1995
Methods Prospective double-blind RCT
Participants 50 women scheduled for the loop excision for treatment of cervical dysplasia were asked
to participate in the study. All agreed to take part. Age and parity was comparable in
both groups
Age: mean (SD) (intervention vs. comparison): 29.5 years (10.5) vs. 28.4 years (8.9)
Parity: mean (SD) (intervention vs. comparison): 2.1 (2.1) vs. 2.3 (1.6)
Loop passes: mean (SD) (intervention vs. comparison): 1.2 (0.4) vs. 1.3 (0.6)
Positive margins: mean (SD) (intervention vs. comparison): 2/25 vs. 3/25
Interventions In the intervention arm, 25 women received cervical application of benzocaine 20% gel
and in comparison arm women received a placebo gel before the procedure. In addition,
all women also received preprocedural oral analgesia ketorolac tromethamine 10 mg
orally 30minutes before procedure. After 1minute of gel application, 1mL of lignocaine
1% with adrenaline 1:100,000 was injected in 1 mL doses into the cervical stroma at the
12, 3, 6 and 9 o’clock positions (total 4 mL) with 25-gauge needle on a needle extender
Outcomes Immediately after the procedure the women were asked to rate on a standard VAS the
pain from injection as well as pain from loop excision procedure. The scale consisted
of 10-cm horizontal line with vertical cross bars at each endpoint. The endpoints were
labelled ’no pain’ and ’worst pain possible’
Notes Other outcomes such as number of passes of the loop or details of margins of the loop
were not included for the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Low risk “By use of computer-generatednumbers, patientswere
randomized to one of two groups”
Allocation: sequence concealment Unclear risk Not reported
Performance and detection: blinding
All outcomes
Low risk “Both patient and physician were unaware which gel
the syringe contained”
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Lipscomb 1995 (Continued)
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 50/50 (100%)
Reporting: unreported outcomes Unclear risk Adverse events of gel were not reported
Other: anything else Low risk No additional form of bias was likely
Mikhail 1988
Methods A randomised prospective double-blind placebo controlled trial
Participants 50 women undergoing laser vaporisation of the cervix for CIN were allocated to 1 of
the 2 groups. There were 25 women in each group. Characteristics of the 2 groups were
recorded
Age: mean (SD) (intervention vs. comparison): 27.4 years (3.9) vs. 26.7 years (4.57)
Parity: mean (SD): (intervention vs. comparison): 0.9 (1.24) vs. 1 (1)
Interventions In the intervention group (N = 25) the cervix was sprayed with 3-4 mL of a cocaine
10% solution preserved in nipasept (a mixture of the methyl, ethyl and propyl esters
of p-hydroxybenzoic acid). The comparison group (N = 25) was sprayed with a similar
quantity of the preservative alone. There was no indication on the spray to identify the
solution. When necessary, additional pain relief was given by the local infiltration of
prilocaine by hypodermic injection. 1 to 2 mL of the solution were sprayed on the cervix
and repeated as necessary through the procedure
Outcomes The time taken to complete the treatment and assessment of the blood loss were noted.
The severity of the pain experienced was assessed at the end of the procedure using
standard 10-mm VAS (Huskisson 1983) and VRS. The VRS consisted of 4 categories -
none, mild, moderate or severe. Blood loss was assessed subjectively by the operator as
minimal, moderate and severe
Notes Mean and SD for each group was calculated fromfigure 1 on page 471 of the publication,
using GraphPad Prism software package, where the graph was enlarged allowing an
accurate estimate of each individuals pain score
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Low risk “The patients were allocated to their groups
by a computer-generated random list”
Allocation: sequence concealment Unclear risk Not reported
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Mikhail 1988 (Continued)
Performance and detection: blinding
All outcomes
Low risk “There was no indication on the spray to
identify the solution ... The randomized
and double-blind nature of the trial elimi-
nated observer bias”
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 50/50 (100%)
Reporting: unreported outcomes Low risk There reason to suspect outcomes were se-
lectively reported
Other: anything else Low risk No additional form of bias was likely
Rogstad 1992
Methods Randomised placebo-controlled double-blind trial
Participants 60 women who were scheduled to undergo cold coagulation for cervical abnormalities
Interventions 21 received lignocaine (intervention) and 31 received normal saline (comparison). Cervix
was infiltrated with 2 mL of lignocaine 2% or 2 mL of normal saline before cold coag-
ulation
Outcomes The degree of pain felt was measured by VRS and VAS
Notes Other outcomes like pain of injection and 3 to 6 weeks’ follow-up questionnaire of pain
and bleeding were excluded from the analysis
Mean and SD for each group was calculated from figure on page 942 of the publication,
using GraphPad Prism software package, where the graph was enlarged allowing an
accurate estimate of each individuals pain score
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Low risk “The trial was randomised, placebo con-
trolled and double-blind. Randomisation
was by computerised generation of random
numbers”
Allocation: sequence concealment Unclear risk Not reported
Performance and detection: blinding
All outcomes
Unclear risk Labelled as double-blind placebo-con-
trolled trial, but details are not documented
in paper
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Rogstad 1992 (Continued)
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 60/60 (100%) for pain out-
come
Reporting: unreported outcomes High risk Adverse events were not reported
Other: anything else Unclear risk Insufficient information to permit judge-
ment
Sammarco 1993
Methods A prospective RCT
Participants Each patient was evaluated by colposcopy with biopsy and had a histological diagnosis of
cervical dysplasia. They were scheduled to undergo cryosurgery. Cryosurgery was carried
out with liquid nitrogen using Cryo-2000 (Valleylab, Boulder, Colorado) by double
freeze technique with a 3-minute freeze and 5-minutes thaw cycle. Nulliparous women,
those under 16 years of age and those with allergies were excluded. Women with no
endocervical disease and lesions of less than 3 cm were eligible
Interventions Both control and intervention group received a single dose of ketoprofen 75 mg (a
non-steroidal anti-inflammatory drug) within 1 hour of procedure, 2 women received
naproxen sodium 550 mg. The control group received no further analgesia. The in-
tervention women received an injection of 2 to 3 mL of lignocaine with a 1:100,000
dilution of adrenaline, which was administered submucosally at the 2 and 10 o’clock
positions with 25-gauge needle 1 minute prior to the cryosurgery
Outcomes A VAS with 0 representing no pain and 10 representing severe pain, was used to evaluate
the amount of pain experienced by the patient
Notes Mean VAS score recorded by nurses was not included in analysis owing to high risk of
bias
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Unclear risk Not reported
Allocation: sequence concealment Unclear risk Not reported
Performance and detection: blinding
All outcomes
High risk “The study was limited since neither the nurse nor the patient
was blinded”
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Sammarco 1993 (Continued)
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 45/49 (92%) for pain outcomes
Reporting: unreported outcomes Unclear risk Adverse events were not reported
Other: anything else High risk Nulliparous women were excluded from the study.Women with
no endocervical disease and lesions of less than 3 cmwere eligible
“Four of the original 49 study patients were excluded from the
final data analysis since they recorded a higher pain score prior
to the procedure than after the procedure and therefore recorded
a negative pain score for unexplained reasons. This included 2
patients in the control group and 2 patients in the study group”
Sarkar 1993
Methods Prospective, random allocation, double-blind, placebo-controlled trial
Participants Women were undergoing laser treatment for CIN in the colposcopy and laser clinic. 35
women were allocated to receive EMLA cream (intervention group) and 35 to receive
placebo cream (comparison group). The following exclusion criteria were used: known
or suspected hypersensitivity to local anaesthetics of amide type, concomitant treatment
with analgesic medication, inability to complete assessment forms and patient’s refusal
to be recruited into the trial
Age: mean (SD) (intervention vs. comparison): 27.8 years (6.3) vs. 28 years (5.4)
Interventions The EMLA and placebo creams were supplied in visually identical metal tubes that were
identified by patient number. 10 minutes before the start of the laser treatment, 10 mL
of cream was applied to the cervix and surrounding area
Outcomes The severity of the pain experienced during the treatment was assessed at the end of the
treatment, using McGill’s pain questionnaire (Melzack 1975), and the VAS (Huskisson
1983). Blood loss during the procedure was reported as none, mild, moderate and
troublesome
Notes Minor adverse experiences during treatment such as feeling hot, sweating, dizziness,
fainting and sickness were not included in analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Unclear risk Not reported
Allocation: sequence concealment Unclear risk Not reported
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Sarkar 1993 (Continued)
Performance and detection: blinding
All outcomes
Low risk “The EMLA and the placebo cream were
supplied in visually identical metal tubes
which were identified by patient number”
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 68/70 (97%) for pattern of
pain outcome
Reporting: unreported outcomes Low risk Pertinent outcomes were reported in the
trial
Other: anything else High risk “When expressing the ’present pain inten-
sity’, some patients indicated a score be-
tween categories, so extra categories were
created, such as 1-5, 2.5 etc”. Such anal-
yses are therefore dubious. Furthermore,
“Whenpatientswere asked todescribe their
present pain by choosing specific words
from
McGill’s pain questionnaire (Melzack,
1975), the EMLA treated group tended
to select words from fewer categories. The
average number of words selected by the
EMLA group was 3.83, compared with 5.
06 for the placebo group (P < 0.05)”. This
probably applies to an average ordinal score
rating rather than average number of words




Participants 60 women scheduled to have LLETZ carried out for CIN were recruited to have the
anaesthetic injection in the cervix before procedure by 2 different techniques
Referral smear (intervention vs. control): mild: 8/32 vs. 5/32; moderate: 12/32 vs. 10/
32; severe: 8/32 vs. 7/32; borderline: 2/32 vs. 3/32; inadequate: 2/32 vs. 0/32; glandular
abnormality: 0/32 vs. 1/32
LLETZ histology: CIN 1: 5/32 vs. 1/32; CIN 2: 7/32 vs. 7/32; CIN 3: 15/32 vs. 17/
32; inflammation: 3/32 vs. 0/32; CGIN: 2/32 vs. 0/32; adenocarcinoma: 0/32 vs. 1/32
Margins: both negative: 24/32 (75%) vs. 17/32 (65%);
positive endocervical margin: 0/32 vs. 2/32;
positive ectocervical margin: 5/32 vs. 6/32
Both positive: 1/32 vs. 0/32
Uncertain: 2/32 vs. 1/32
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Winters 2009 (Continued)
Interventions Both groups received a total of 8.8 mL (4 ampoules) of prilocaine 3% with felypressin
(Citanest, AstraZeneca, UK). The control group received four 2.2 mL ampoules of
prilocaine with felypressin injected deep into the cervical stroma at 8 equally spaced
points around the circumference of the cervical TZ, using a 35-mm 27-gauge dental
needle. In the intervention group the injection technique differed in that one 2.2 mL
ampoule of prilocaine with felypressin was injected just under the epithelium, in 4 areas
circumferentially, in order to raise a blanch. Then three 2.2 mL ampoules were injected
in 8 places circumferentially deep into the cervical stroma
Outcomes Following completion of treatment, women were asked to indicate on separate 100-
mm VAS the pain they experienced during administration of local anaesthetic and then
during the actual LLETZ procedure
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation: sequence generation Low risk “The block randomisation code was computer gener-
ated”
Allocation: sequence concealment Low risk “Randomisation was performed by opening sequen-
tially numbered, sealed envelopes in order of recruit-
ment”
Performance and detection: blinding
All outcomes
High risk “Participants were blinded to the technique of admin-
istration of local anaesthetic, by necessity the colpo-
scopist could not be blinded to this”
Detection: blind outcome assessment
All outcomes
Unclear risk Not reported
Attrition: incomplete outcome data
All outcomes
Low risk % analysed: 58/60 (%)
Reporting: unreported outcomes High risk Adverse events of injections were not reported
Other: anything else Low risk No additional form of bias was likely
CGIN: cervical glandular intraepithelial neoplasia; CIN: cervical intraepithelial neoplasia; HAD: Hospital Anxiety and Depression
scale; HPV: human papillomavirus; LLETZ: large loop excision of the transformation zone; RCT: randomised controlled trial; SD:
standard deviation; TENS: transcutaneous electric nerve stimulation; TZ: transformation zone; VAS: visual analogue scale; VRS:
verbal rating score.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Sarkar 1990 Not an RCT
Sharp 2009 Pain relief interventions were not part of trial scope
RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Local anaesthetic (lignocaine 2%) injection versus control (saline injection)




participants Statistical method Effect size
1 Pain scores during procedure
(VAS)
2 130 Mean Difference (IV, Random, 95% CI) -13.74 [-34.32, 6.
83]
1.1 Paracervical block versus
placebo
1 70 Mean Difference (IV, Random, 95% CI) -3.0 [-16.03, 10.03]
1.2 Direct cervical infiltration
versus placebo
1 60 Mean Difference (IV, Random, 95% CI) -24.0 [-35.44, -12.
56]
2 Moderate to severe pain 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Comparison 2. Local anaesthetic plus vasoconstrictor versus control




participants Statistical method Effect size
1 Pain scores during procedure
(VAS: 0-100)
2 95 Mean Difference (IV, Random, 95% CI) -23.73 [-37.53, -9.
93]
1.1 Lignocaine plus adrenaline 1 45 Mean Difference (IV, Random, 95% CI) -31.10 [-43.74, -18.
46]
1.2 Prilocaine plus felypressin 1 50 Mean Difference (IV, Random, 95% CI) -17.0 [-28.19, -5.81]
2 Moderate or severe pain 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
2.1 versus placebo 1 92 Risk Ratio (IV, Random, 95% CI) 0.12 [0.04, 0.37]
2.2 versus no treatment 1 50 Risk Ratio (IV, Random, 95% CI) 0.73 [0.42, 1.27]
3 Troublesome bleeding 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Comparison 3. Local anaesthetic plus vasoconstrictor versus local anaesthetic injection alone




participants Statistical method Effect size
1 Moderate or severe pain 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
2 Blood loss (volume) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
3 Duration of treatment 1 Mean Difference (IV, Random, 95% CI) Subtotals only
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Comparison 4. Prilocaine plus felypressin versus lignocaine plus adrenaline




participants Statistical method Effect size
1 Pain (using 6 category scale) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 Blood loss (0-5 scale) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 5. Deep plus superficial versus deep cervical injection




participants Statistical method Effect size
1 Pain scores during procedure
(VAS: 0-100)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 6. Oral analgesic versus control




participants Statistical method Effect size
1 Pain scores (VAS: 0-100) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 versus placebo 2 129 Mean Difference (IV, Random, 95% CI) -3.51 [-10.03, 3.01]
1.2 versus no treatment 1 32 Mean Difference (IV, Random, 95% CI) -4.0 [-13.69, 5.69]
2 Moderate to severe pain 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
3 Pain relief required in first 24
hours
1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Comparison 7. Inhalation analgesia versus placebo




participants Statistical method Effect size
1 Pain scores (VAS: 0-100) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 Heavy vaginal bleeding 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
3 Anxiety - HAD score 1 Mean Difference (IV, Random, 95% CI) Subtotals only
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Comparison 8. Topical application versus placebo




participants Statistical method Effect size
1 Pain scores during procedure
(VAS: 0-100)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 Duration of treatment 1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 9. Cocaine spray versus placebo




participants Statistical method Effect size
1 Pain scores during procedure
(VAS: 0-100)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 Moderate to severe pain 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
3 Troublesome bleeding 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Comparison 10. TENS versus TENS plus local anaesthetic injection




participants Statistical method Effect size
1 Troublesome blood loss 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Comparison 11. TENS versus local anaesthetic injection




participants Statistical method Effect size
1 Troublesome blood loss 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
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Comparison 12. TENS plus local versus local anaesthetic injection




participants Statistical method Effect size
1 Troublesome blood loss 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Local anaesthetic (lignocaine 2%) injection versus control (saline injection),
Outcome 1 Pain scores during procedure (VAS).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 1 Local anaesthetic (lignocaine 2%) injection versus control (saline injection)
Outcome: 1 Pain scores during procedure (VAS)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Paracervical block versus placebo
Johnson 1989 35 27 (30.6) 35 30 (24.7) 48.9 % -3.00 [ -16.03, 10.03 ]
Subtotal (95% CI) 35 35 48.9 % -3.00 [ -16.03, 10.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 Direct cervical infiltration versus placebo
Rogstad 1992 29 29 (22.1) 31 53 (23.1) 51.1 % -24.00 [ -35.44, -12.56 ]
Subtotal (95% CI) 29 31 51.1 % -24.00 [ -35.44, -12.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
Total (95% CI) 64 66 100.0 % -13.74 [ -34.32, 6.83 ]
Heterogeneity: Tau2 = 181.38; Chi2 = 5.64, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 5.64, df = 1 (P = 0.02), I2 =82%
-20 -10 0 10 20
Favours local Favours placebo
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Analysis 1.2. Comparison 1 Local anaesthetic (lignocaine 2%) injection versus control (saline injection),
Outcome 2 Moderate to severe pain.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 1 Local anaesthetic (lignocaine 2%) injection versus control (saline injection)
Outcome: 2 Moderate to severe pain
Study or subgroup Local anaesthetic Placebo Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Rogstad 1992 7/29 21/31 0.36 [ 0.18, 0.71 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (Local anaesthetic), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours local Favours placebo
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Analysis 2.1. Comparison 2 Local anaesthetic plus vasoconstrictor versus control, Outcome 1 Pain scores
during procedure (VAS: 0-100).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 2 Local anaesthetic plus vasoconstrictor versus control









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Lignocaine plus adrenaline
Sammarco 1993 19 11.6 (15) 26 42.7 (27.8) 47.7 % -31.10 [ -43.74, -18.46 ]
Subtotal (95% CI) 19 26 47.7 % -31.10 [ -43.74, -18.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.82 (P < 0.00001)
2 Prilocaine plus felypressin
Lee 1986 25 26 (18.3) 25 43 (21.9) 52.3 % -17.00 [ -28.19, -5.81 ]
Subtotal (95% CI) 25 25 52.3 % -17.00 [ -28.19, -5.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.98 (P = 0.0029)
Total (95% CI) 44 51 100.0 % -23.73 [ -37.53, -9.93 ]
Heterogeneity: Tau2 = 62.33; Chi2 = 2.68, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 3.37 (P = 0.00075)
Test for subgroup differences: Chi2 = 2.68, df = 1 (P = 0.10), I2 =63%
-20 -10 0 10 20
Favours local+vasoconst. Favours placebo
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Analysis 2.2. Comparison 2 Local anaesthetic plus vasoconstrictor versus control, Outcome 2 Moderate or
severe pain.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 2 Local anaesthetic plus vasoconstrictor versus control




strictor Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 versus placebo
Duncan 2005 3/45 26/47 100.0 % 0.12 [ 0.04, 0.37 ]
Subtotal (95% CI) 45 47 100.0 % 0.12 [ 0.04, 0.37 ]
Total events: 3 (Local + vasoconstrictor), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.69 (P = 0.00022)
2 versus no treatment
Lee 1986 11/25 15/25 100.0 % 0.73 [ 0.42, 1.27 ]
Subtotal (95% CI) 25 25 100.0 % 0.73 [ 0.42, 1.27 ]
Total events: 11 (Local + vasoconstrictor), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 8.03, df = 1 (P = 0.00), I2 =88%
0.1 0.2 0.5 1 2 5 10
Favours local+vasoconst. Favours control
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Analysis 2.3. Comparison 2 Local anaesthetic plus vasoconstrictor versus control, Outcome 3 Troublesome
bleeding.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 2 Local anaesthetic plus vasoconstrictor versus control




strictor Control Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Lee 1986 2/25 5/25 0.40 [ 0.09, 1.87 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (Local + vasoconstrictor), 5 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours local+vasoconst. Favours control
Analysis 3.1. Comparison 3 Local anaesthetic plus vasoconstrictor versus local anaesthetic injection alone,
Outcome 1 Moderate or severe pain.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 3 Local anaesthetic plus vasoconstrictor versus local anaesthetic injection alone




strictor Local alone Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Diakomanolis 1997 12/50 10/50 1.20 [ 0.57, 2.52 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (Local +vasoconstrictor), 10 (Local alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours local+vasoconst. Favours local alone
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Analysis 3.2. Comparison 3 Local anaesthetic plus vasoconstrictor versus local anaesthetic injection alone,
Outcome 2 Blood loss (volume).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 3 Local anaesthetic plus vasoconstrictor versus local anaesthetic injection alone









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Diakomanolis 1997 50 30.25 (3.1) 50 39 (5.2) -8.75 [ -10.43, -7.07 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 3.3. Comparison 3 Local anaesthetic plus vasoconstrictor versus local anaesthetic injection alone,
Outcome 3 Duration of treatment.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 3 Local anaesthetic plus vasoconstrictor versus local anaesthetic injection alone









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Diakomanolis 1997 50 17.53 (1.2) 50 25.25 (2.5) -7.72 [ -8.49, -6.95 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 4.1. Comparison 4 Prilocaine plus felypressin versus lignocaine plus adrenaline, Outcome 1 Pain
(using 6 category scale).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 4 Prilocaine plus felypressin versus lignocaine plus adrenaline
Outcome: 1 Pain (using 6 category scale)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Howells 2000 94 0.45 (0.73) 106 0.5 (0.79) -0.05 [ -0.26, 0.16 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours prilocaine + Favours lignocaine +
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Analysis 4.2. Comparison 4 Prilocaine plus felypressin versus lignocaine plus adrenaline, Outcome 2 Blood
loss (0-5 scale).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 4 Prilocaine plus felypressin versus lignocaine plus adrenaline
Outcome: 2 Blood loss (0-5 scale)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Howells 2000 94 1.74 (0.98) 106 1.33 (1.05) 0.41 [ 0.13, 0.69 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours prilocaine + Favours lignocaine +
Analysis 5.1. Comparison 5 Deep plus superficial versus deep cervical injection, Outcome 1 Pain scores
during procedure (VAS: 0-100).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 5 Deep plus superficial versus deep cervical injection
Outcome: 1 Pain scores during procedure (VAS: 0-100)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Winters 2009 32 7.7 (9.1) 26 12.6 (15.1) -4.90 [ -11.51, 1.71 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours superficial Favours cervical
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Analysis 6.1. Comparison 6 Oral analgesic versus control, Outcome 1 Pain scores (VAS: 0-100).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 6 Oral analgesic versus control
Outcome: 1 Pain scores (VAS: 0-100)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 versus placebo
Al Kurdi 1985 50 36 (23.1) 47 41 (23.1) 50.2 % -5.00 [ -14.20, 4.20 ]
Frega 1994 11 19 (13) 21 21 (12) 49.8 % -2.00 [ -11.24, 7.24 ]
Subtotal (95% CI) 61 68 100.0 % -3.51 [ -10.03, 3.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
2 versus no treatment
Frega 1994 11 19 (13) 21 23 (13.8) 100.0 % -4.00 [ -13.69, 5.69 ]
Subtotal (95% CI) 11 21 100.0 % -4.00 [ -13.69, 5.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
-10 -5 0 5 10
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Analysis 6.2. Comparison 6 Oral analgesic versus control, Outcome 2 Moderate to severe pain.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 6 Oral analgesic versus control
Outcome: 2 Moderate to severe pain
Study or subgroup Oral analgesic Placebo Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Al Kurdi 1985 28/50 32/47 0.82 [ 0.60, 1.13 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 28 (Oral analgesic), 32 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours oral analgesic Favours placebo
Analysis 6.3. Comparison 6 Oral analgesic versus control, Outcome 3 Pain relief required in first 24 hours.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 6 Oral analgesic versus control
Outcome: 3 Pain relief required in first 24 hours
Study or subgroup Oral analgesic Placebo Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Al Kurdi 1985 2/48 17/47 0.12 [ 0.03, 0.47 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (Oral analgesic), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours oral analgesic Favours placebo
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Analysis 7.1. Comparison 7 Inhalation analgesia versus placebo, Outcome 1 Pain scores (VAS: 0-100).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 7 Inhalation analgesia versus placebo
Outcome: 1 Pain scores (VAS: 0-100)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cruickshank 2005 194 22.4 (25.1) 195 29.6 (27.7) -7.20 [ -12.45, -1.95 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
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Analysis 7.2. Comparison 7 Inhalation analgesia versus placebo, Outcome 2 Heavy vaginal bleeding.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 7 Inhalation analgesia versus placebo
Outcome: 2 Heavy vaginal bleeding
Study or subgroup Gas Placebo Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Cruickshank 2005 52/175 44/173 1.17 [ 0.83, 1.64 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 52 (Gas), 44 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours gas Favours placebo
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Analysis 7.3. Comparison 7 Inhalation analgesia versus placebo, Outcome 3 Anxiety - HAD score.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 7 Inhalation analgesia versus placebo
Outcome: 3 Anxiety - HAD score





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cruickshank 2005 191 7.3 (4.11) 196 7.29 (4.06) 0.01 [ -0.80, 0.82 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 8.1. Comparison 8 Topical application versus placebo, Outcome 1 Pain scores during procedure
(VAS: 0-100).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 8 Topical application versus placebo
Outcome: 1 Pain scores during procedure (VAS: 0-100)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lipscomb 1995 25 62 (82) 25 71 (128) -9.00 [ -68.59, 50.59 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours benzocaine gel Favours placebo
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Analysis 8.2. Comparison 8 Topical application versus placebo, Outcome 2 Duration of treatment.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 8 Topical application versus placebo
Outcome: 2 Duration of treatment





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sarkar 1993 35 6.1 (3.4) 35 6 (2.9) 0.10 [ -1.38, 1.58 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours EMLA cream Favours placebo
Analysis 9.1. Comparison 9 Cocaine spray versus placebo, Outcome 1 Pain scores during procedure (VAS:
0-100).
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 9 Cocaine spray versus placebo
Outcome: 1 Pain scores during procedure (VAS: 0-100)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mikhail 1988 25 28 (15.9) 25 56 (19.5) -28.00 [ -37.86, -18.14 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours cocaine spray Favours placebo
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Analysis 9.2. Comparison 9 Cocaine spray versus placebo, Outcome 2 Moderate to severe pain.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 9 Cocaine spray versus placebo
Outcome: 2 Moderate to severe pain
Study or subgroup Cocaine Placebo Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Mikhail 1988 12/25 21/25 0.57 [ 0.37, 0.89 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (Cocaine), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours cocaine spray Favours placebo
Analysis 9.3. Comparison 9 Cocaine spray versus placebo, Outcome 3 Troublesome bleeding.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 9 Cocaine spray versus placebo
Outcome: 3 Troublesome bleeding
Study or subgroup Cocaine Placebo Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Mikhail 1988 0/25 11/25 0.04 [ 0.00, 0.70 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Cocaine), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours cocaine spray Favours placebo
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Analysis 10.1. Comparison 10 TENS versus TENS plus local anaesthetic injection, Outcome 1 Troublesome
blood loss.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 10 TENS versus TENS plus local anaesthetic injection
Outcome: 1 Troublesome blood loss
Study or subgroup TENS
TENS plus
local
anaesthetic Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Crompton 1992 3/34 1/29 2.56 [ 0.28, 23.29 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (TENS), 1 (TENS plus local anaesthetic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours TENS Favours TENS plus local
Analysis 11.1. Comparison 11 TENS versus local anaesthetic injection, Outcome 1 Troublesome blood loss.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 11 TENS versus local anaesthetic injection
Outcome: 1 Troublesome blood loss
Study or subgroup TENS Local anaesthetic Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Crompton 1992 3/34 4/35 0.77 [ 0.19, 3.20 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (TENS), 4 (Local anaesthetic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours TENS Favours local
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Analysis 12.1. Comparison 12 TENS plus local versus local anaesthetic injection, Outcome 1 Troublesome
blood loss.
Review: Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
Comparison: 12 TENS plus local versus local anaesthetic injection




anaesthetic Local anaesthetic Risk Ratio Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Crompton 1992 1/29 4/35 0.30 [ 0.04, 2.55 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (TENS plus local anaesthetic), 4 (Local anaesthetic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours TENS plus local Favours local
A D D I T I O N A L T A B L E S




Al Kurdi 1985 97 women, undergoing
CO2 laser treatment for
CIN
Aged 18 to 50 years




Comparison group: (N =
47)
2 placebo tablets
Given no less than 30
minutes before procedure
Pain relief:
VAS on 10-cm scale
VRS: (none, very slight,
mild, moderate, severe)
Speed of procedure
Use of analgesia in first 24
hours
Self-reported side effects
were very minor (aches
andpains at 24hours) and
not included in analysis
Connell 2000 30 women undergoing
LLETZ
Aged 20 to 64 years




Comparison group: (N =
15)
saline spray
Both group received 4.4
Pain relief:
VAS on 100-mm scale
and
4-point categorical scale
1-4; 1 = not painful; 2
= slightly painful; 3 =
moderately painful; 4 =
severely painful
The outcome reported on
categorical scale was not
included in the analysis
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Table 1. Overview of included studies (Continued)





Crompton 1992 98 women undergoing






, age and parity were
recorded to assess group
comparability
3-arm trial
(1) TENS (N = 34) vs.
(2) TENS plus direct in-
filtration of 2 mL ligno-
caine 2% plus octapressin
1:10,000 (0.03 IU/mL)
(N = 29)
(3) Direct infiltration of
2 mL lignocaine 2% plus
octapressin (N = 35)
Pain relief: VAS on 120-
mm scale
Median pain score was on
120-mm VAS; however,
authors converted it to
percentage for reporting
Cruickshank 2005 389 women undergo-
ing LLETZ treatment for
CIN
Mean age for intervention
group 32.7 years and for
control 31.5 years




Comparison group: (N =
194)
placebo (air)
Both groups also re-
ceived infiltration of the








Anxiety using HAD scale
Acceptability, satisfac-
tion, helpfulness and will-
ingness to undergo proce-
dures in future - not in-
cluded in analysis
Diakomanolis 1997 100 women undergoing
CO2 laser for CIN.
Median age for interven-
tion group 28 years and
for comparison group 28.
5 years
Intervention group: (N =
50)




nocaine only): (N = 50)
30 mL of lignocaine 1%
solution
Pain relief:




Side effects - transient hy-
pertension and sweating
Duncan 2005 97 women undergoing
treatment with Semm co-
agulator
Intervention: N = 46,
mean age 31.3 (SD 8.4)
Comparison: N = 47,
mean age 32.6 (SD 8.0)
Nullipara: intervention:
Intervention group: (N =
46)
5-mL vials of prilocaine
3% (30 mg/mL) with fe-
lypressin 0.03 IU/mL





1-3, mild; 4-7, moderate;
8-10, severe pain
Details of anticipated
pain were excluded from
the analysis
61Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.














CIN1 = 17/47 (36.2%),
CIN2,3 = 29/47 (61.7%)
, microinvasion = 1/47 (2.
1%)





mg 30 minutes before
treatment, N = 21
(2) Placebo 30 minutes
before treatment, N = 21
and
(3) No drug, N = 21
Pain relief on
VAS 100-mm scale
Howells 2000 200 women, aged 20-60
years, undergo-
ing LLETZ forCIN (final
histology was negative for
4/94 in intervention arm
and 8/106 in comparison
arm)
Characteristic for prilo-
caine with felypressin (N
= 94) vs. lignocaine with
adrenaline (N = 106)
Age (years) - mean (SD):
36.6 (10.3) vs. 34.6 (9.7)
Intervention group: (N =
94)
prilocaine 3% (30 mg/
mL) with felypressin 0.03
IU/mL (Citanest)
Comparison group: (N =
106)
lignocaine
2% with adrenaline 1:80,
000 (xylocaine)
Duration of procedure
Degree of bleeding (0 =
none; 5 = heavy)
Pain relief:
patient reported (0 =
none; 5 = unbearable)
Other side effects, such as
feeling faint, nausea and
shaking, were also scored
in
a similar fashion (0 =
none; 5 = a great deal)
Johnson 1989 70 women undergoing
CO2 laser ablation for
cervical dysplastic lesion
Size of transformation
zone was recorded as a





eral paracervical block by
injecting 10 mL into the
paracervical tissues
Intervention group: (N =
35)
lignocaine 2%
Comparison group: (N =
35)
Pain relief:
VAS on 120-mm scale
and objective scoring by
nurse and attending oper-
ator





syndrome scores were also
recorded
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Table 1. Overview of included studies (Continued)
normal saline
Johnson 1996 44 women undergoing
CO2 laser treatment for
CIN
Intervention group: (N =
23)
10 mL of paracervical 2%
lignocaine
Comparison group: (N =
21)
2mLof lignocaine 2%di-
rectly into the TZ
Pain relief:
VAS (expressed as per-
centage) and
objective scoring by nurse
and laser operator
Lee 1986 50 women under-
going laser vaporisation of
cervix for CIN
Intervention group: (N =
25)
ectocervix was infiltrated
with 2 mL of citanest
(prilocaine 3% with 0.03
IU/mL of felypressin)
Control group: (N = 25)
no analgesia or anaesthe-
sia
Pain relief:
VAS on 100-mm scale
(VRS none, mild, moder-
ate or severe)
Blood loss: none, slight,
moderate, troublesome
Side effects such as sweat-
ing, nausea, dizziness and
cramps were also reported
but not included in analy-
sis as theywereminor side
effects
Lipscomb 1995 50 women scheduled for
the loop electrosurgical
excision for treatment of
CIN
Age - mean (SD): inter-
vention group: 29.5 (10.
5) and comparison group:
28.4 (8.9)
Parity - mean (SD): inter-
vention group: 2.1 (2.1)
and comparison group: 2.
3 (1.6)
Loop passes: mean (SD)
: intervention group: 1.




group: 2/25 and compar-
ison group: 3/25




Comparison group: (N =
25)
placebo gel
After 1 minute of gel ap-
plication, 4 mL of ligno-
caine 1% with adrenaline
1:100,000 was injected in
cervix
Pain relief:
VAS on 10-cm scale
Mikhail 1988 50 women undergoing




age: 27.4 (3.9); parity: 0.
9 (1.24)
Intervention group: (N =
25)
cervix was sprayedwith 3-
4mLof a cocaine 10% so-
lution






VAS on 100-mm scale
and
VRS: none, mild, moder-
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Table 1. Overview of included studies (Continued)
Comparison group:
age: 26.7 (4.57); parity: 1
(1)
cervix sprayed with a sim-
ilar quantity of the preser-
vative alone
ate or severe
Rogstad 1992 60 women undergoing
cold coagulation for cer-
vical abnormalities
Intervention group: (N =
29)
2 mL of lignocaine 2%




VAS on 0 to 10 scale and
VRS
Other
outcomes like pain of in-
jection and 3-6weeks’ fol-
low-up questionnaire of
pain and bleeding were
excluded from the analy-
sis
Sammarco 1993 45 women undergoing
cryocoagulation with liq-
uid nitrogen using cryo-
2000 by double-freeze
technique for CIN
Intervention group: (N =
19)
2-3 mL of lignocaine 1%
+ adrenaline 1:100,000
dilution
Comparison group: (N =
26)
no treatment
Both groups also re-
ceived single dose of ke-
toprofen 75 mg, within
1 hour of the proce-
dure; 2 women received
naproxen sodium 550 mg
Pain relief:
VAS on 100-mm scale
Mean VAS score recorded
by nurses was not in-
cluded in analysis owing
to high risk of bias
Sarkar 1993 70 women undergoing
laser treatment for CIN
Age mean (SD): EMLA
cream: 27.8 years (6.3)
and placebo: 28 years (5.
4)
Intervention group: (N =
35)
EMLA cream (lignocaine
2.5% and prilocaine 2.
5%)
Comparison group: (N =
35)
placebo cream
Pain relief: assessed by
McGill’s pain question-
naire (Melzack 1975) and
the
VAS




such as feeling hot, sweat-
ing, dizziness, fainting
and sickness were not in-
cluded in analysis
Winters 2009 60 women undergoing
LLETZ for CIN
Intervention group: (N =
30)
prilocaine 3% with fe-
lypressin injected deep
into the cervical stroma
around TZ
Comparison group: (N =
30)
prilocaine 3% with fe-
lypressin injected super-
ficial followed by deep
into the cervical stroma
around TZ
Pain relief:
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Table 1. Overview of included studies (Continued)
Same amount used for
both groups
CIN: cervical intraepithelial neoplasia; HAD: Hospital Anxiety and Depression; HPV: human papillomavirus; LLETZ: loop excision
of the transformation zone; SD: standard deviation; TENS: transcutaneous electrical nerve stimulation; VAS: visual analogue scale;
VRS: verbal rating score; TZ: transformation zone.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Analgesia explode all trees
#2 MeSH descriptor Anesthetics explode all trees
#3 MeSH descriptor Analgesics explode all trees
#4 MeSH descriptor Pain explode all trees with qualifiers: DT,TH
#5 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal explode all trees
#6 analgesia or analgesic*
#7 anesthetic* or anaesthetic*
#8 anti-inflammator*
#9 transcutaneous electrical nerve stimulation or TENS
#10 pain next/3 (relief or drug* or therap* or treat*)
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 MeSH descriptor Uterine Cervical Neoplasms explode all trees
#13 MeSH descriptor Cervical Intraepithelial Neoplasia explode all trees
#14 MeSH descriptor Uterine Cervical Dysplasia explode all trees
#15 cervi* near/5 (intraepithel* or dysplasia or cancer* or tumor* or tumour* or neoplas* or carcinoma* or malignan*)
#16 CIN or CIN1 or CIN2 or CIN3
#17 (#12 OR #13 OR #14 OR #15 OR #16)




#22 excis* or ablat* or laser* or cryosurg*
#23 (#18 OR #19 OR #20 OR #21 OR #22)
#24 (#11 AND #17 AND #23)
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Appendix 2. MEDLINE search strategy




4 exp Pain/dt, th [Drug Therapy, Therapy]
5 exp Anti-Inflammatory Agents, Non-Steroidal/
6 (pain adj3 (relief or drug* or therap* or treat*)).mp.
7 (analgesia or analgesic*).mp.
8 (anesthetic* or anaesthetic*).mp.
9 anti-inflammator*.mp.
10 (Transcutaneous Electrical Nerve Stimulation or TENS).mp.
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
12 exp Uterine Cervical Neoplasms/
13 Cervical Intraepithelial Neoplasia/
14 Uterine Cervical Dysplasia/
15 (cervi* adj5 (intraepithel* or dysplasia or cancer* or tumor* or tumour* or neoplas* or carcinoma* or malignan*)).mp.
16 (CIN or CIN1 or CIN2 or CIN3).mp.





22 (excis* or ablat* or laser* or cryosurg*).mp.
23 18 or 19 or 20 or 21 or 22
24 11 and 17 and 23
key:
mp=title, original title, abstract, name of substance word, subject heading word, unique identifier
Appendix 3. EMBASE search strategy
EMBASE Ovid 1980 to present
1 exp analgesia/
2 exp anesthetic agent/
3 exp analgesic agent/
4 exp pain/dt, th [Drug Therapy, Therapy]
5 exp nonsteroid antiinflammatory agent/
6 (pain adj3 (relief or drug* or therap* or treat*)).mp.
7 (analgesia or analgesic*).mp.
8 (anesthetic* or anaesthetic*).mp.
9 anti-inflammator*.mp.
10 transcutaneous nerve stimulation/
11 (transcutaneous electrical nerve stimulation or TENS).mp.
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13 exp uterine cervix tumor/
14 uterine cervix dysplasia/
15 uterine cervix carcinoma in situ/
16 (cervi* adj5 (intraepithel* or dysplasia or cancer* or tumor* or tumour* or neoplas* or carcinoma* or malignan*)).mp.
17 (CIN or CIN1 or CIN2 or CIN3).mp.
18 13 or 14 or 15 or 16 or 17
19 colposcopy/
20 colposcop*.mp.
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21 LLETZ.mp.
22 LEEP.mp.
23 (excis* or ablat* or laser* or cryosurg*).mp.
24 19 or 20 or 21 or 22 or 23
25 12 and 18 and 24
key:
mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer
H I S T O R Y
Protocol first published: Issue 3, 2006
Review first published: Issue 10, 2012
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We did not identify any ongoing trials so the following sentence was removed from the ’searching other resources section’:
• “If ongoing trials which have not been published are identified through these searches, the principal investigators will be
approached for relevant data.”
The review included 17 trials but comparisons were restricted to single trial analyses or meta-analysis of few trials so the following
section on reporting biases was removed:
• “Assessment of reporting biases Funnel plots corresponding to meta-analysis of the primary outcome will be examined to
assess the potential for small study effects. When there is evidence of small-study effects, publication bias will be considered as only
one of a number of possible explanations. If these plots suggest that treatment effects may not be sampled from a symmetric
distribution, as assumed by the random effects model, sensitivity analyses will be performed using fixed effects models.”
Subgroup analyses were not carried out so we removed the following section:
• “Subgroup analysis and investigation of heterogeneity If possible, subgroup analysis will be performed, grouping the trials by
different routes of administering analgesia i.e. oral, injectable or inhalation and pain relief for different treatment types. Factors such
as age, CIN grade, length of follow-up, adjusted/unadjusted analysis will be considered in interpretation of any heterogeneity.”
We did not carry out sensitivity analysis. We had specified the following in the protocol:
• “Sensitivity analysis We will perform sensitivity analyses excluding studies at moderate or high risk of bias.”
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Analgesics [∗administration & dosage]; Cervical Intraepithelial Neoplasia [∗surgery]; Colposcopy [∗adverse ef-
fects]; Drug Therapy, Combination [methods]; Intraoperative Complications [∗therapy]; PainManagement [∗methods]; PainMeasure-
ment; Pain, Postoperative [∗therapy]; Randomized Controlled Trials as Topic; Transcutaneous Electric Nerve Stimulation [methods];
Uterine Cervical Neoplasms [∗surgery]
MeSH check words
Adult; Female; Humans
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